

# A rational roadmap for SARS-CoV-2/COVID-19 pharmacotherapeutic research and development. IUPHAR review “XXX”

SPH Alexander, J Armstrong, AP Davenport, J Davies, E Faccenda, SD Harding, F Levi-Schaffer, JJ Maguire, AJ Pawson, C Southan. MJ Spedding

Steve PH Alexander\*, University of Nottingham, Chair, Nomenclature and Standards Committee of the International Union of Basic and Clinical Pharmacology (NC-IUPHAR) 0000-0003-4417-497X [steve.alexander@nottingham.ac.uk](mailto:steve.alexander@nottingham.ac.uk)

Jane Armstrong, University of Edinburgh, Curator, Guide to PHARMACOLOGY (GtoPdb) 0000-0002-0524-0260 [jane.armstrong@ed.ac.uk](mailto:jane.armstrong@ed.ac.uk)

Anthony P Davenport, University of Cambridge, Executive Committee, NC-IUPHAR 0000-0002-2096-3117 [apd10@medschl.cam.ac.uk](mailto:apd10@medschl.cam.ac.uk)

Jamie Davies, University of Edinburgh, Principal Investigator, Guide to PHARMACOLOGY (GtoPdb), Executive Committee, NC-IUPHAR 0000-0001-6660-4032 [Jamie.Davies@ed.ac.uk](mailto:Jamie.Davies@ed.ac.uk)

Elena Faccenda, University of Edinburgh, Curator, Guide to PHARMACOLOGY (GtoPdb) 0000-0001-9855-7103 [e.faccenda@ed.ac.uk](mailto:e.faccenda@ed.ac.uk)

Simon D Harding, University of Edinburgh, Database Developer, Guide to PHARMACOLOGY (GtoPdb) 0000-0002-9262-8318 [simon.harding@igmm.ed.ac.uk](mailto:simon.harding@igmm.ed.ac.uk)

Francesca Levi-Schaffer, Hebrew University of Jerusalem, First Vice-President and Chair of Immunopharmacology Section, International Union of Basic and Clinical Pharmacology (IUPHAR) 0000-0003-0620-2810 [francescal@ekmd.huji.ac.il](mailto:francescal@ekmd.huji.ac.il)

Janet J Maguire, University of Cambridge 0000-0002-9254-7040 [jjm1003@medschl.cam.ac.uk](mailto:jjm1003@medschl.cam.ac.uk)

Adam J Pawson, University of Edinburgh, Senior Curator, Guide to PHARMACOLOGY (GtoPdb), Executive Committee, NC-IUPHAR 0000-0003-2280-845X [adam.pawson@ed.ac.uk](mailto:adam.pawson@ed.ac.uk)

Christopher Southan, Deanery of Biomedical Sciences, University of Edinburgh, and TW2Informatics Ltd, Gothenburg, 42166, Sweden 00-0001-9580-0446 [cdsouthan@hotmail.com](mailto:cdsouthan@hotmail.com)

Michael J Spedding, Secretary-General, International Union of Basic and Clinical Pharmacology (IUPHAR) and Spedding Research Solutions SAS, France 0000-0002-1247-8221 [michael@speddingresearchsolutions.fr](mailto:michael@speddingresearchsolutions.fr)

\*Author for correspondence, Division of Physiology, Pharmacology and Neuroscience, School of Life Sciences, University of Nottingham NG7 7LP ENGLAND [steve.alexander@nottingham.ac.uk](mailto:steve.alexander@nottingham.ac.uk)

### Keywords

COVID-19; SARS-CoV-2; proteinase; RNA polymerase;

### Abbreviations

3CL<sub>pro</sub>, 3C-like proteinase of the virus  
ACE, angiotensin-converting enzyme  
ACE2, angiotensin-converting enzyme 2  
ADRP, ADP-ribose-1''-phosphatase  
ARDS, acute respiratory distress syndrome  
BPS, British Pharmacological Society  
CARD, caspase activation and recruitment domain  
CoV, coronavirus  
E, Envelope protein of the virus  
FRET, Förster Resonance Energy Transfer  
GtoPdb, BPS/IUPHAR Guide to PHARMACOLOGY database  
IUPHAR, International Union of Basic and Clinical Pharmacology  
M, Membrane glycoprotein of the virus  
MERS, Middle East respiratory syndrome  
N, Nucleocapsid protein of the virus  
nsp, non-structural protein of the virus  
PAMP, pathogen-associated molecular pattern  
PL<sub>pro</sub>, papain-like proteinase of the virus  
RBD, receptor binding domain  
S, Spike glycoprotein of the virus  
SADS, Swine Acute Diarrhoea Syndrome  
SARS, severe acute respiratory syndrome  
TM, transmembrane

### Author contributions

The document was conceived in discussions among SPHA, JA, JD, EF, SDH, FLS, AJP, CS and MJS; it was initially drafted by SPHA and all the co-authors contributed text and checked the manuscript; all the authors read and agree to submission of the manuscript.

### Conflict of Interests

None of the authors has a conflict of interest to declare.

## Abstract

In this review, we identify opportunities for drug discovery in the treatment of COVID-19 and in so doing, provide a rational roadmap whereby pharmacology and pharmacologists can mitigate against the global pandemic. We assess the scope for targetting key host and viral targets in the mid-term, by first screening these targets against drugs already licensed; an agenda for drug re-purposing, which should allow rapid translation to clinical trials. A simultaneous, multi-pronged approach using conventional drug discovery methodologies aimed at discovering novel chemical and biological means targetting a short-list of host and viral entities should extend the arsenal of anti-SARS-CoV-2 agents. This longer-term strategy would provide a deeper pool of drug choices for future-proofing against acquired drug resistance. Second, there will be further viral threats, which will inevitably evade existing vaccines. This will require a coherent therapeutic strategy which pharmacology and pharmacologists are best placed to provide.

## Introduction

PubMed has already accumulated a vast repository of information on SARS-CoV-2/COVID-19, which increases on a daily basis (on 2020-03-23, there were 1369 hits for COVID-19; this number more than doubled in the space of two weeks, so that by 2020-04-06 there were 2780 hits in PubMed for COVID-19). Clearly, there is a need to summarise this information critically and prioritise the elements which are constructive and useful for each individual sector. This document suggests priorities for how drug discovery and development might be rationally focussed for the rapid identification and successful translation of therapeutic agents to treat COVID-19.

Given the urgency of the current situation, clearly initial drug discovery should focus on repurposing licensed drugs, as dosage and safety information are largely to hand. Unfortunately, there is controversy over proof of efficacy for essentially all the potential repurposed agents for which preliminary, and, in many cases, non-peer reviewed data have surfaced. Some of this controversy is addressed below but efforts are underway from both WHO and NIH to coordinate larger, higher powered and better controlled studies in an attempt to demonstrate efficacy unequivocally. As a 'second wave', *de novo* discovery focussing on novel agents may allow future refinement and capacity to treat patients who are unable to be treated by, or are unresponsive to, the repurposed agents, but it would be very unlikely to have these new drugs available to treat the current crisis.

The IUPHAR/BPS Guide to PHARMACOLOGY ([GtoPdb](#)) is an open-access database, developed by the International Union of Basic and Clinical Pharmacology (IUPHAR) and the British Pharmacological Society (BPS). It provides expert-curated descriptions of almost 3,000 human proteins and over 10,000 ligands, including more than 1400 approved drugs. Management of the new resource is the responsibility of the Nomenclature and Standards Committee of IUPHAR ([NC-IUPHAR](#)), which acts as the scientific advisory and editorial board. The committee has an international network of over 700 expert volunteers organized into ~60 subcommittees dealing with individual target families. The database is notably enhanced through the continued linking of relevant pharmacology with key immunological data types as part of the IUPHAR [Guide to IMMUNOPHARMACOLOGY](#) (supported by the Wellcome Trust) and by a major new extension, the IUPHAR/MMV [Guide to Malaria PHARMACOLOGY](#) (in partnership with the Medicines for Malaria Venture). The GtoPdb team centred at the University of Edinburgh have constructed a resource ([Faccenda et al.](#)), which provides a precis of the current understanding about the virus and potential associated drug targets and drugs. As with the other databases, the emphasis of the curation process is on stringent provenancing of the information provided, although inevitably the current situation limits the capacity for triangulation of data.

## Nomenclature

Sequencing analysis of the novel virus has identified a high level of similarity with the virus identified to cause the Severe Acute Respiratory Syndrome (SARS) outbreak in China in 2002/03/04, which was known as the SARS coronavirus or SARS-CoV. Provisionally named as 2019-nCoV, the virus has been

renamed SARS-CoV-2 (Viruses, 2020). For the purposes of this document, the virus is described as SARS-CoV-2, while the infectious disease is named as COVID-19 (World Health Organization, 2020). One of the positive aspects of the emergence of SARS-CoV-2 and COVID-19 is the rapidity at which aspects like genome sequencing (for example, Lu *et al.*, 2020; Wu *et al.*, 2020) and 3D structures (for example, Yan *et al.*, 2020) have been described.

Protein targets and drugs in the current review follow nomenclature as presented on the GuidetoPHARMACOLOGY.org website (Alexander, Ball & Tsoleridis. [SARS-CoV-2 proteins](#), accessed on 2020-04-24) and the Concise Guide to Pharmacology 2019/20 (Alexander *et al.*, 2019).

## The viral cycle and virally-encoded potential drug targets

For general reviews of the coronaviruses, see Masters, 2006; Fehr and Perlman, 2015; de Wit *et al.*, 2016; Zumla *et al.*, 2016; Cui *et al.*, 2019; Desforges *et al.*, 2019; Song *et al.*, 2019. SARS-CoV-2 is a betacoronavirus; a lipid-enveloped, single-stranded, positive sense RNA virus. Other human coronaviruses include alphacoronaviruses, such as human coronavirus-229E (HCoV-229E), and betacoronaviruses, such as SARS-CoV and MERS-CoV (responsible for the Middle East respiratory syndrome) (for review, see Zumla *et al.*, 2016; Corman *et al.*, 2018; Pillaiyar *et al.*, 2020). More than 200 viral types have been associated with the common cold, of which 50% of infections are rhinovirus, but also include respiratory syncytial virus, influenza and coronaviruses, particularly HCoV-229E. Although HCoV-229E is regarded as 'relatively benign' since monocytes are much more resistant to infection, it does rapidly kill dendritic cells (Mesel-Lemoine *et al.*, 2012).

Classically, the viral lifecycle can be divided into six elements: cell attachment; cell entry; viral uncoating; nucleotide replication; viral assembly, and release (see **Figure 1**). Positive-stranded RNA viruses replicate in the cytoplasm of infected cells, in close contact with intracellular membranes. This organization allows a concentration of viral and host factors to enable virus production and to evade innate immune responses (reviewed by Yager and Konan, 2019).

The SARS-CoV-2 coronavirus 30 kb genome encodes 29 proteins has 15 open reading frames, two of which encode viral polyproteins that generate 16 non-structural proteins (see below) (Wu *et al.*, 2020). Historically, therapeutic benefit has been gained through exploitation of the differences between viral and host proteins that subserve superficially similar functions (proteases and nucleotide polymerases, for example). The rapidity with which structural elements of the SARS-CoV-2 proteome have been identified provides hope that drug discovery approaches will soon provide agents to target the virus selectively, with minimal impact on the host. Based on the evidence from orthologous proteins from other betacoronaviruses and the information currently available on SARS-CoV-2 (some of it not yet from peer-reviewed sources), we propose here the priority targets for pharmacological investigation. That should not be taken to mean that research should be limited to these targets, since there are undoubtedly a number of functions of the viral proteins still to be ascertained. It would be remiss not to conduct a thorough examination of all the viral proteome, both in isolation and in combination. The strategies we learn from investigation of the host:viral interaction from SARS-CoV-2 will stand us in good stead for future viral threats.

## Cellular attachment and entry; replication, assembly and release

Coronavirus binds to cell surface proteins on target cells and, following proteinase priming of spike proteins on the virus surface, the virus is internalized into endosomal fractions that are subsequently acidified, or accumulates through a non-endosomal route (Fehr and Perlman, 2015) (Figure 1). The endosomal route appears to involve clathrin (Inoue *et al.*, 2007), but there are contradictory reports of the importance of the intracellular C-terminus of ACE2 in this mechanism (Inoue *et al.*, 2007; Haga *et al.*, 2008). A fusion domain permits insertion of a key protein (S, see below), which then allows mixing of the viral and cellular membranes and subsequent release of the coronaviral genome into the cytoplasm.

Following entry into the host cell cytoplasm and viral uncoating, the replicase gene of the viral RNA is translated. The genome of coronaviruses consists of a single, continuous, linear, ssRNA, capped at

the 5' end and with a 3'-polyA tail (Fehr and Perlman, 2015). Translation occurs from open reading frame (ORF) 1a and 1b at the 5' terminus, with a ribosomal frameshifting mechanism allowing the overlap between *ORF1a* and *ORF1b* to generate the two polyproteins [pp1a](#) and [pp1ab](#) (Fehr and Perlman, 2015; Perlman and Netland, 2009; Snijder et al., 2003; Thiel et al., 2003). In SARS-CoV-2, the polyproteins are long, 4405 and 7096 aa, respectively. Encoded within the polyproteins of betacoronaviruses are two proteinases: papain-like proteinase, PL<sub>pro</sub>, and [chymotrypsin-like proteinase](#), 3CL<sub>pro</sub>. In SARS-CoV, PL<sub>pro</sub>, derived from the polyproteins, has three endoproteinase target sites, which release nsp1-3 (Thiel et al., 2003). 3CL<sub>pro</sub> has 11 cleavage sites to release the remaining non-structural proteins. In the coronavirus family, these proteinases process the polyproteins to generate 16 functional non-structural proteins identified as nsp1-16 (Anand et al., 2003; Thiel et al., 2003; Ziebuhr et al., 2007; Kindler et al., 2016; Cui et al., 2019).

Downstream of the ORF1a and 1b are genes encoding four structural proteins ([Spike](#), [Envelope](#), [Membrane](#) and [Nucleocapsid](#)) (**Figure 2**) and a short series (described as at least 13 in total, Srinivasan et al., 2020) of other proteins (see below). Once sufficient protein and RNA accumulate, coronavirus assembly takes place, centred on the structural proteins. The release of coronavirus particles involves the secretory pathway of the endoplasmic reticulum and Golgi apparatus and vesicular exocytosis (for review, see de Haan and Rottier, 2005; Fehr and Perlman, 2015), and it is likely, but as yet unconfirmed, that SARS-CoV-2 adopts this mechanism also.

To date, there is more evidence about the molecular detail involved in (and the possibilities to modify) viral recognition, entry and replication compared to uncoating, assembly and release, hence the attention paid here to the former three mechanisms.

## Targetting virus recognition and cellular entry

### The cell-surface anchor - ACE2

Among the coronaviruses, the spike protein interacts with proteinases to anchor on host cell surfaces. The cell-surface anchoring point for the alphacoronavirus HCoV-229E is [aminopeptidase N](#) (also known as CD13, Yeager et al., 1992). For the betacoronavirus MERS-CoV, [dipeptidylpeptidase 4](#) (also known as CD26, Raj et al., 2013) is an anchor. Analysis of the co-crystal structure suggested that the SARS spike protein binds to the active site of angiotensin converting enzyme 2 ([ACE2](#), Li et al., 2005). Binding of SARS-CoV spike to ACE2 seems to require cholesterol-rich rafts in the host cells (Glende et al., 2008). Recent evidence points to the spike protein of SARS-CoV-2 also binding to ACE2. Both SARS-CoV (Li et al., 2003) and SARS-CoV-2 (Hoffmann et al., 2020; Letko et al., 2020) have been described to require ACE2 to enter cells (Figure 1). A particular domain of the spike protein of SARS-CoV-2, a so-called Receptor-Binding Domain (RBD), has been shown to facilitate binding to ACE2 (Hoffmann et al., 2020). The ACE2 peptidase active site is located remotely from the cell membrane (Li et al., 2005; Wrapp et al., 2020; Yan et al., 2020), into which the Spike protein binds. The RBD of the Spike protein is located in the S1 ectodomain, approximately a third of the way along the protein. ACE2 is a carboxypeptidase, which means it removes the terminal amino acid from oligopeptides, and so it seems unlikely that the Spike protein is a substrate for ACE2.

In SARS-CoV-infected mouse lung, ACE2 protein expression was downregulated compared to uninfected mice (Kuba et al., 2005). Following SARS-CoV Spike protein administration to mice, angiotensin II was increased in the lungs (Kuba et al., 2005). These observations led to the suggestion that this was the molecular mechanism for the frequent development of acute respiratory distress syndrome (ARDS) during SARS-CoV infections (Imai et al., 2005; Kuba et al., 2005).

ACE2 activity has been reported to be released from plasma membranes by proteolysis, thought to be through the action of TNF $\alpha$  convertase ([ADAM17](#), A Disintegrin And Metalloproteinase domain containing protein 17, Lambert et al., 2005) (**Figure 1**). The activity of ADAM17 can be increased by G protein-coupled receptor activation, including the AT1 angiotensin receptor (Schafer et al., 2004). ACE2, and ACE, activity can be measured in human plasma (Ocaranza et al., 2006; Herath et al., 2007; Lew et al., 2008). Human plasma ACE2 activity is reported to be 'masked' by the presence of



endogenous inhibitors (Lew *et al.*, 2008), which don't yet appear to have been precisely defined. Blood ACE2 activity can be altered in pathology; for example, serum ACE2 was found to be decreased in patients following acute ischemic stroke (Bennion *et al.*, 2016).

The expression of ACE2 mRNA and enzyme activity in cardiac tissues were increased following repeated oral administration of the [AT<sub>1</sub> angiotensin II receptor](#) antagonist [losartan](#), while oral administration of an ACE inhibitor [lisinopril](#) only increased cardiac mRNA expression, but not enzyme activity (Ferrario *et al.*, 2005).

Studies using disruption of the *ace2* gene in mice indicated an increase in circulating angiotensin II levels and a severe cardiac contractility defect, which could be 'rescued' with simultaneous genetic disruption of ACE (Crackower *et al.*, 2002). An early investigation of ACE2 polymorphisms in man failed to show an association with hypertension (Benjafield *et al.*, 2004). A study of SARS victims and ACE2 polymorphisms failed to find a correlation with patient outcomes (Chiu *et al.*, 2004).

### The coronaviral Spike protein

The spike protein is the largest viral structural protein (~1200-1400 aa) and is heavily glycosylated, forming extended trimeric structures providing the characteristic 'crown' feature of coronaviruses (Belouzard *et al.*, 2012) (see **Figure 2**). The ectodomain is divided into the S1 domain responsible for binding to ACE2, whereas the S2 domain is responsible for the fusion machinery. Following binding of the S1 domain to ACE2, a deformation of the pre-fusion trimer results (Wrapp *et al.*, 2020). Surface plasmon resonance of the binding of human ACE2 to the immobilized SARS-CoV-2 indicated an affinity ( $K_d$  value) of 15 nM, an order of magnitude larger than SARS-CoV binding to ACE2 (Wrapp *et al.*, 2020). Using a related label-free technique, biolayer interferometry, affinities of 5 and 1.2 nM for binding of SARS-CoV and SARS-CoV-2 spike protein, respectively, to human ACE2 has been reported (Walls *et al.*, 2020).

Although a proteolytic cleavage site at the S1/S2 boundary of the SARS-CoV Spike protein is the best characterised, a second site upstream of the fusion peptide in the S2 domain, called S2' has also been described (Belouzard *et al.*, 2009). This raises the possibility that multiple other proteases might be targeted to influence coronavirus activation (Millet and Whittaker, 2015). A key difference between the Spike proteins in SARS-CoV and SARS-CoV-2 is the presence in the latter of a site at the S1/S2 boundary predicted to be sensitive to the proteinase [furin](#), and which may be targeted during viral assembly and maturation (Walls *et al.*, 2020).

The SARS-CoV S2 domain has a pair of  $\alpha$ -helices, which may participate in coiled:coil structures during membrane fusion (Petit *et al.*, 2005). The host complex of ZDHHC9 ([Link to UniProt](#)) with GOLGA7 ([Link to UniProt](#)), a palmitoyltransferase, which modifies the low molecular weight G proteins [NRAS](#) and [HRAS](#) (Swarthout *et al.*, 2005), also palmitoylates the cysteine-rich S2 endodomain of the SARS-CoV to facilitate membrane fusion (Petit *et al.*, 2007).

Very recently, in a comparison of the S2 domains of SARS-CoV and SARS-Cov-2, an enhanced capacity of the novel virus' S2 domain for membrane fusion was observed and suggested to result from eight differing amino acids (Xia *et al.*, 2020). Using a series of oligopeptides conjugated to lipid entities, high affinity (IC<sub>50</sub> values in the nanomolar range) inhibitors of cell fusion were identified.

### Interfering with the ACE2:Spike interaction

Given that the spike protein binds to the active site of ACE2 (Li *et al.*, 2005), in theory, any alteration in the availability of the active site should influence the binding of the spike protein and, hence, interfere with SARS-CoV-2 infection. One option would be to provide an excess of an endogenous peptide substrate, or more conventionally to apply a selective enzyme inhibitor.

### Endogenous substrates of ACE2

ACE2, discovered in 2000 (Donoghue *et al.*, 2000), shares 40% sequence similarity to ACE within the N-terminal domain and is a type I transmembrane metallopeptidase. Unlike ACE, it functions as a zinc carboxypeptidase to cleave single C-terminal amino acids from peptides, particularly hydrolysing Pro-Phe residues in angiotensin-(1-8) to angiotensin-(1-7), [Pyr<sup>1</sup>]-apelin 13 to [Pyr<sup>1</sup>]-apelin-(1-12) and

263 [des-Arg<sup>9</sup>]-bradykinin to bradykinin-(1-8) with high efficiency. It may also cleave other peptides less  
264 effectively (Vickers *et al.*, 2002), shown below:

<a href="#">Angiotensin I</a>	⇒	<a href="#">angiotensin-(1-9)</a> + Leu
<a href="#">Angiotensin II</a>	⇒	<a href="#">angiotensin-(1-7)</a> + Phe
<a href="#">Apelin-(1-13)</a>	⇒	QRPRLSHKGMP + Phe
<a href="#">Apelin-(1-36)</a>	⇒	....QRPRLSHKGMP + Phe
<a href="#">[Des-Arg<sup>9</sup>]-Bradykinin</a>	⇒	RPPGFSP + Phe
<a href="#">Dynorphin A-(1-13)</a>	⇒	YGGFLRRIRPKL + Lys

265 115 other peptides were not hydrolysed by ACE2 including adrenocorticotrophic hormone,  
266 calcitonin, cholecystokinin, met-enkephalin, glucagon, glucagon-like peptide-1, melanin-  
267 concentrating hormone, pituitary adenylyl cyclase-activating polypeptide, somatastatin-14, urocortin  
268 or vasoactive polypeptide (Vickers *et al.*, 2002).

269 In humans, levels of mRNA encoding ACE2, together with immunoreactive peptide, are highest in the  
270 gastrointestinal tract, followed by heart, kidney, testes and gall bladder and other tissues (Uhlen *et al.*,  
271 2015). Within organs, ACE2 immunoreactivity was predominantly localised to epithelial (for  
272 example, in the lungs) and endothelial cells from all vascular beds examined (Yang *et al.*, 2017).  
273 Importantly, the ACE2 antisera used in this study for immunocytochemistry was the same as that  
274 employed in the study described in the section below “Using biopharmaceutical/antibody  
275 approaches to target ACE2:Spike interactions” (Hoffmann *et al.*, 2020), to block entry of the virus in  
276 cell culture. The epitope of this antisera would be a rational starting point for the development of  
277 selective therapeutic antibodies.

278 The presence of ACE2 on airway epithelial cells is consistent with the isolation of SARS-CoV-2 from  
279 broncho-alveolar lavage of patients with COVID19 and the infection of cultured airway epithelial  
280 cells (Zhu *et al.*, 2020). In humans, levels of ACE2 immunoreactivity tend to be low. However, in  
281 addition to being upregulated by ACE inhibitors and angiotensin receptor antagonists (see above),  
282 ACE2 expression has been reported to be increased in human cardiovascular disease, for example, in  
283 the cardiomyopathic heart (Zisman *et al.*, 2003). Since ACE2 is critical for viral entry, it may be one  
284 explanation for the high incidence of co-morbidity of COVID-19 patients with cardiovascular disease.

#### 285 *Manipulation of ACE2 activity by synthetic agents*

286 Assays employing fluorogenic surrogate substrates to screen for inhibitors of ACE2 activity are well-  
287 established, for example using methoxycoumarin-RPPGFSAFK(Dnp)-OH (Ocaranza *et al.*, 2006;  
288 Bennion *et al.*, 2016), or methoxycoumarin-APK(Dnp)OH (Herath *et al.*, 2007; Lew *et al.*, 2008;  
289 Mores *et al.*, 2008). Detailed protocols for the use of methoxycoumarin-APK(Dnp)OH have been  
290 described for FRET-based high throughput screening (Sriramula *et al.*, 2017; Xiao and Burns, 2017).

291 This style of assay identified that ACE2 was not inhibited in the presence of 10 µM lisinopril,  
292 enalaprilat, or captopril, inhibitors of [angiotensin-converting enzyme](#) (Tipnis *et al.*, 2000). There are  
293 no licensed drugs described to inhibit ACE2 activity. However, DX600 is a peptide-based ACE2  
294 inhibitor (Huang *et al.*, 2003), while MLN4760 and compound 28 are described as sub-nanomolar  
295 potency ACE2 inhibitors (Mores *et al.*, 2008).

296 There is evidence for allosteric regulation of ACE2 activity, in that a xanthone derivative ([XNT](#)) was  
297 observed to **enhance** ACE2, but not ACE, activity *in vitro* with a potency of 20 µM (Hernandez Prada  
298 *et al.*, 2008). An *in silico* study later identified a binding site in an allosteric hinge region of ACE2,  
299 distinct from the proteinase active site, against which 1217 FDA-approved drugs were screened  
300 (Kulemina and Ostrov, 2011). A subsequent kinetic assay with the recombinant enzyme and a  
301 fluorogenic substrate identified [labetalol](#) and [diminazene](#) as agents able to double the maximal  
302 velocity of ACE2 enzyme activity.

303 Whether any of these compounds alter the binding of the spike protein from either SARS-CoV or  
304 SARS-CoV-2 or viral infection in general does not appear to have been examined yet.

305 A speculative area that should be explored further is the concept of enhancing the activity of the  
306 serine proteinase ADAM17 to increase cleavage and release of membrane bound ACE2. Peptides

such as angiotensin II are reported in animal models to cause release ('shedding') following binding to AT<sub>1</sub> receptors (Xu *et al.*, 2017). Although angiotensin II is licensed by the Federal Drug Administration to treat sepsis (known as Giapreza, Davenport *et al.*, 2020), it would be inadvisable as a treatment for COVID-19 given the detrimental action of angiotensin II on the lungs. In contrast, the investigational agent [Pyr<sup>1</sup>]-apelin-13 is currently used in clinical studies (Davenport *et al.*, 2020) and may also interact with its cognate receptor to downregulate membrane-expressed ACE2. This peptide also has beneficial effects on the heart, including an increase in cardiac output (Japp *et al.*, 2010).

#### *Using biopharmaceutical/antibody approaches to target ACE2:Spike interactions*

An alternative approach to the small molecule manipulation of the ACE2 enzyme would be to target the spike or ACE2 proteins with selective antibodies. Antibodies directed against ACE2 led to a reduction in SARS-CoV-2 virus entry into target cells (Hoffmann *et al.*, 2020), although this is likely to be some distance away from a therapeutic application.

A truncated version of human recombinant ACE2, lacking the transmembrane domain, mitigated against SARS-CoV infection of cells (Li *et al.*, 2003) and has been used in animal models to reduce symptoms of severe acute lung failure (Imai *et al.*, 2005), diabetic nephropathy (Oudit *et al.*, 2010) and cardiac hypertrophy and fibrosis (Zhong *et al.*, 2010). Treating SARS-CoV-2 victims with a soluble form of ACE2 (Batlle *et al.*, 2020) or a fusion protein of the spike-binding portion of ACE2 combined with the Fc portion of human IgG (Lei *et al.*, 2020) has been suggested.

Apeiron Biologics has approval to conduct a Phase II clinical trial of APN01 (human recombinant ACE2) for the treatment of COVID-19 in three European countries (Austria, Germany and Denmark) ([NCT04335136](#)). This recombinant version of ACE2 was originally licensed to GlaxoSmithKline and previously tested as GSK2586881 in a Phase 2 multicentre trial ([NCT01597635](#)) in patients with lung injury or ARDS, both features of SARS and MERS (and now COVID-19). The study tested the hypothesis that cleavage of angiotensin II (which causes lung injury - vasoconstriction, inflammation, fibrosis, vascular leak, and sodium absorption) to angiotensin-(1-7), would have counter regulatory beneficial action and reduce long term injury. GSK2586881 was well-tolerated in patients with ARDS, and the rapid modulation of peptides of the renin-angiotensin system demonstrated target engagement, in that levels of angiotensin II decreased rapidly whereas angiotensin-(1-7) levels increased and remained elevated for 48 h, although the study was not powered to detect changes in acute physiology or clinical outcomes (Khan *et al.*, 2017).

Sera from convalescent SARS-CoV patients prevented the cell entry of SARS-CoV-2 (Hoffmann *et al.*, 2020) and this approach has been used with some success in the SARS, MERS and COVID-19 outbreaks (for review, see Bloch *et al.*, 2020). The difficulty in identifying the precise molecular mechanism/s of convalescent sera action and issues with collection, standardization and scaling-up will be a challenge (Bloch *et al.*, 2020).

A bacterial equivalent of ACE2 (based on 3D structure rather than primary sequence) termed B38-CAP has been described, which is reported to reduce hypertension and limit cardiac dysfunction in an animal model (Minato *et al.*, 2020). Whether this agent might provide a decoy anchor to 'chelate' viral particles prior to cell entry has not been investigated.

In a preliminary (as yet, not peer reviewed) study, a conformational change in the S1 RBD of the SARS-CoV-2 Spike protein in the presence of heparin was noted (Mycroft-West *et al.*, 2020). Cell-surface heparan sulphate glycosaminoglycans have previously been suggested to be a lactoferrin-sensitive alternative attachment point for the SARS-CoV virus (Lang *et al.*, 2011). These observations suggest further routes for pharmacological targetting of viral infection and propagation.

#### *The cell-surface priming mechanism - TMPRSS2*

TMPRSS2 is a single transmembrane domain protein with an extracellular serine protease domain, which appears to cleave substrates preferentially at basic residues (arg/lys), with a calcium-binding LDL receptor class A domain (Paoloni-Giacobino *et al.*, 1997). The *TMPRSS2* gene encodes a cell-



surface proteinase (transmembrane serine protease 2, [TMPRSS2](#)) and is located at chromosomal locus 21q22.3 in close proximity to *ERG*, a gene encoding an ETS transcription factor ([Link to UniProt](#), Paoloni-Giacobino *et al.*, 1997). (*ERG* fusion with *EWS* leads to Ewing's sarcoma) Fusion of the *TMPRSS2* and *ERG* (or the related *ETV1*) genes has been reported to occur in the majority of prostate cancers and is suggested to lead to an androgen-dependent amplification of ETS-regulated genes (Tomlins *et al.*, 2005). *TMPRSS2* expression is androgen-regulated (Lin *et al.*, 1999; Chen *et al.*, 2019); it is expressed highly in prostate cancer (Lin *et al.*, 1999; Lucas *et al.*, 2008) (for review, see Tanabe and List, 2017) and loss of *TMPRSS2* in the prostate is associated with reduced metastatic potential (Lucas *et al.*, 2014). In aggressive versions of prostate cancer, *TMPRSS2* undergoes autocatalytic proteolysis at Arg<sup>255</sup>-Ile<sup>256</sup> (Afar *et al.*, 2001), where the two chains may remain in combination due to interchain disulphide bridges (Chen *et al.*, 2010) or the catalytic moiety may be secreted (Chen *et al.*, 2010). In LNCaP human prostate cancer cells, the PPAR $\alpha$  agonist fenofibrate was able to mitigate against the androgen receptor agonist-evoked increase in *TMPRSS2* expression (Zhao *et al.*, 2013). Following binding of the S protein to ACE2, *TMPRSS2* 'primes' the spike protein to facilitate entry of the virus into the target cell (Hoffmann *et al.*, 2020; Matsuyama *et al.*, 2020). Pathogenesis of two strains of influenza virus has been reported to be markedly diminished by gene disruption of *tmprss2* in mice (Hatesuer *et al.*, 2013; Tarnow *et al.*, 2014), inferring that targeting this enzyme may have antiviral potential.

#### [Interfering with the \*TMPRSS2\*:Spike interaction](#)

Using immunohistochemical analysis (Bertram *et al.*, 2012) and, very recently, using single nuclei and single cell RNA sequencing (Lukassen *et al.*, 2020), as yet not peer reviewed) of lung samples from otherwise healthy subjects, ACE2 and *TMPRSS2* were shown to be co-expressed in human bronchial epithelial cells, which could be a nexus for primary infection. A similar approach identified co-expression of ACE2 and *TMPRSS2* in nasal goblet cells, lung type II pneumocytes and small intestine absorptive epithelia (Ziegler *et al.*, 2020). In the same study, human primary nasal epithelial cells showed an upregulation in ACE2 expression following 12 h incubation with [interferon- \$\alpha\$ 2](#) and [interferon- \$\gamma\$](#) , which suggests the potential for a feed-forward mechanism whereby the virus interacts preferentially with 'activated' cells to suppress the innate immune response (see below) (Ziegler *et al.*, 2020).

By analogy with the previous consideration of ACE2 (above), alternatives to manipulate *TMPRSS2* activity would be to provide endogenous substrates or synthetic inhibitors. However, the potential to make use of endogenous substrates seems limited. Thus, although *TMPRSS2* has been described to hydrolyse and activate the cell-surface G protein-coupled receptor [proteinase-activated receptor 2](#) (Wilson *et al.*, 2005), mice lacking *tmprss2* failed to display an overt phenotype (Kim *et al.*, 2006).

As with ACE2, there are no reports of licensed drugs which inhibit *TMPRSS2* activity. Cbz-GGR-aminomethylcoumarin has been described as a surrogate fluorogenic substrate suitable for high-throughput screening (Paszti-Gere *et al.*, 2016), although it is also a substrate for other proteinases, such as chymotrypsin. I432, a 3-amidinophenylalanine, has been described as a high affinity selective inhibitor (compound 92, K<sub>i</sub> of 0.9 nM) of *TMPRSS2* (Meyer *et al.*, 2013). In IPEC-J2 pig jejunal epithelial cells, 10-50  $\mu$ M I432 reduced *TMPRSS2*-derived product in cell media (Paszti-Gere *et al.*, 2016).

In an investigation of SARS-CoV entry into HeLa cells expressing recombinant ACE2 and *TMPRSS2*, a number of serine proteinase inhibitors ([benzamidine](#), [aprotinin](#), [gabexate](#), tosyl lysyl chloromethyl ketone and [camostat](#)) were tested (mostly) at 10  $\mu$ M for 30 min before exposure to pseudotyped viruses. Only camostat was effective at reducing viral entry (Kawase *et al.*, 2012), and further experiment suggested that 1  $\mu$ M camostat was also effective, but only when *TMPRSS2* was expressed. At 10 and 50  $\mu$ M, camostat inhibited cell entry of the SARS-CoV and SARS-CoV-2 spike protein (Hoffmann *et al.*, 2020). A direct inhibition of *TMPRSS2* activity appears not to have been reported for camostat.

#### [Potential ancillary proteins for virus entry - B<sup>0</sup>AT1/SLC6A19 and B<sup>0</sup>AT3/SLC6A18](#)

The SLC6 family of transporters includes the well-characterised NET, SERT and DAT monoamine transporters, as well as the less well-exploited [neutral amino acid transporter subfamily](#). B<sup>0</sup>AT1/SLC6A19 and B<sup>0</sup>AT3/SLC6A18 allow sodium- and chloride-dependent accumulation of neutral, aliphatic amino acids at the apical membranes of epithelial cells in the small intestine (B<sup>0</sup>AT1/SLC6A19) and kidney (B<sup>0</sup>AT1/SLC6A19 and B<sup>0</sup>AT3/SLC6A18) (for review, see Broer and Gether, 2012). B<sup>0</sup>AT3/SLC6A18 is also highly expressed in the GI tract and gall bladder ([Protein Atlas](#)) and may play a role in the faecal:oral transmission of coronavirus (Yeo *et al.*, 2020). The cell-surface expression of these neutral amino acid transporters is dependent on co-expression of ACE2 (Kowalczyk *et al.*, 2008; Fairweather *et al.*, 2012), [aminopeptidase N](#) (Fairweather *et al.*, 2012) or collectrin (an adaptor protein, which has high homology to the transmembrane region of ACE2, Camargo *et al.*, 2009, [Link to UniProt](#)), in an apparently tissue-dependent manner (Kuba *et al.*, 2010). A recent cryo-EM structure suggested that ACE2 and B<sup>0</sup>AT1/SLC6A19 form a heterodimer which pairs up through interfaces between the two ACE2 partners (Figure 1), with the RBD of SARS-CoV-2 spike protein binding to the peptidase active site of ACE2 (Yan *et al.*, 2020) suggesting that B<sup>0</sup>AT1/SLC6A19 may facilitate entry of the novel coronavirus. In the small intestine, absorptive epithelial cells were identified to co-express mRNAs encoding for ACE2 and TMPRSS2 (Ziegler *et al.*, 2020). Although it is not yet tested, it would be attractive to speculate that the colocalized expression of these targets may play a role in the faecal:oral transmission of coronavirus (Yeo *et al.*, 2020).

#### [Interfering with the neutral amino acid transporters](#)

Assays for B<sup>0</sup>AT1/SLC6A19 and B<sup>0</sup>AT3/SLC6A18 tend to be traditional accumulation of amino acids labelled with ionising or stable isotopes. Recently, a primary screen using a membrane potential-sensitive fluorescence-based assay was used and followed up with a stable isotope accumulation assay to identify a novel inhibitor, [cinromide](#), which exhibited modest potency (0.3-0.4  $\mu$ M) for inhibiting B<sup>0</sup>AT1/SLC6A19 in cell-based assays (Danthi *et al.*, 2019).

### [Targetting viral uncoating and replication](#)

#### [Viral uncoating](#)

Once inside the cell, the endosomal cysteine proteases [cathepsin B](#) and [cathepsin L](#) have been described to process SARS-CoV (Simmons *et al.*, 2005) and this appears to be maintained for SARS-CoV-2 (Hoffmann *et al.*, 2020) although the significance of such intracellular proteinase activity is unclear. Potent inhibitors for these two proteinases have been reported as pharmacological probes, but there are no licensed drugs identified to target them.

Following entry into the cell, many viruses accumulate in acidified lysosome-like vesicles, and so weak bases (including ammonium chloride and chloroquine) which target the lysosome have been used *in vitro* to target this mechanism. Ammonium chloride (at 20 mM) has been described as a non-specific inhibitor of viral replication *in vitro*, targeting viral uncoating (Mizzen *et al.*, 1985) and, at 50 mM, ammonium chloride inhibited cell entry of both SARS-CoV and SSARS-CoV-2 (Hoffmann *et al.*, 2020). Chloroquine was also observed to reduce infection of L cells by mouse hepatitis virus 3 (Krzystyniak and Dupuy, 1984).

#### [Viral replication](#)

Following entry into the cell, the virus subverts nucleotide, protein, lipid and carbohydrate turnover of the host cell to produce multiple copies of itself. The viral RNA is translated into multiple proteins to produce the replication machinery. As protein translation from the viral genome occurs, the two polyproteins are the first to be synthesised, with the two intrinsic proteases able to cleave the polyproteins into their constituent products.

#### [Targetting the viral proteinases](#)

The low sequence similarities between mammalian and viral proteases has allowed successful drug targetting of viral diseases, including both HIV/AIDS and HCV/hepatitis C. The genome of SARS-CoV-2 contains two proteinases intrinsic to the polyproteins, PL<sub>pro</sub> and 3CL<sub>pro</sub>.

#### The papain-like proteinase, PL<sub>pro</sub>

The more N-terminally-located PL<sub>pro</sub> is the larger (~2000 aa) of the two proteins (for review, see Baez-Santos *et al.*, 2015; Lei *et al.*, 2018), and, in SARS-CoV, is a membrane-associated, polyfunctional entity (Harcourt *et al.*, 2004). Sequence modelling of SARS-CoV-2 PL<sub>pro</sub> suggested the presence of 6TM domains towards the C terminus, with the majority of the protein extending into the cell cytoplasm (Angeletti *et al.*, 2020). In other coronaviruses, the enzyme is also capable of hydrolysing ubiquitin from protein substrates (Barretto *et al.*, 2005; Ratia *et al.*, 2006), as well as removing the ubiquitin-like protein interferon-stimulated gene 15 (ISG, [Link to UniProt](#)) from ISG-conjugated proteins (Yang *et al.*, 2014). Using the orthologous proteinase from the mouse hepatitis coronavirus, analysis of three distinct structural domains suggested that the papain-like proteinase domain coincided with the deubiquitinating and deISGylating functions (Chen *et al.*, 2015). In SARS-CoV, the PL<sub>pro</sub> also contains an ADRP functional phosphatase domain directed at ADP-ribose-1''-phosphates, although the functional significance of the hydrolase activity may be less impactful than the capacity to bind ADP-ribose, at least for the enzyme from HCoV-229E (Putics *et al.*, 2005). This domain is thought to contribute to processing of the viral subgenomic RNAs and the suppression of the innate immune system through reducing interferon production (Lei *et al.*, 2018). Investigating the peptidase activity of SARS-CoV PL<sub>pro</sub> suggested a preference for larger proteins (ubiquitinated or ISGylated) rather than simpler fluorescent-tagged oligopeptide substrates (Lindner *et al.*, 2005; Lindner *et al.*, 2007; Baez-Santos *et al.*, 2014; Ratia *et al.*, 2014) making screening more complicated.

#### The chymotrypsin-like proteinase, 3CL<sub>pro</sub>

The smaller proteinase from SARS-CoV-2 is 3CL<sub>pro</sub> (sometimes called the main prote(in)ase, M<sub>pro</sub>). *In silico* docking models of SARS-CoV-2 3CL<sub>pro</sub> has led to suggestions that particular existing antiviral agents, including velpatasvir and ledipasvir (licensed agents for treating hepatitis C when combined with sofosbuvir in the UK), should be screened for functional activity (Chen *et al.*, 2020). A recent screen of ~10 000 compounds including approved drugs, candidate drugs and natural products used a substrate derived from the N-terminal autocleavage site of the SARS-CoV-2 3CL<sub>pro</sub> which was modified (methylcoumarinylacetyl-AVLQSGFR-Lys(Dnp)-Lys-NH<sub>2</sub>) to allow a FRET-based assay (Jin *et al.*, 2020). The same substrate was used in a screen of the equivalent enzyme from the another coronavirus, HCoV-HKU1, which transferred to humans (Zhao *et al.*, 2008).

A number of inhibitors of the SARS-CoV 3CL<sub>pro</sub> proteinase have been described (Lu *et al.*, 2006; Yang *et al.*, 2006; Goetz *et al.*, 2007), without progressing into the clinic. Recently, an *in silico* approach using orthologues of the SARS-CoV 3CL<sub>pro</sub> from other coronaviruses and enteroviruses allowed production and testing in vitro of a series of  $\alpha$ -ketoamides (Zhang *et al.*, 2020). One compound ([11r](#)) exhibited submicromolar potency against SARS-CoV 3CL<sub>pro</sub> in a cell-free FRET-based assay, and micromolar potency in a cell infection assay with SARS-CoV (Zhang *et al.*, 2020).

In a preliminary (not yet peer-reviewed) report, the SARS-CoV-2 3CL<sub>pro</sub> expressed in HEK293 cells was found to interact with histone deacetylase 2 ([HDAC2](#)) by affinity purification/mass spectrometry (Gordon *et al.*, 2020b). A number of approved drugs target HDAC2 in the treatment of various T cell lymphomas, including [romidepsin](#), [belinostat](#), and [vorinostat](#) with nanomolar potency (Bradner *et al.*, 2010).

#### Targeting nucleotide turnover

A relatively large proportion of the viral genome is inevitably devoted to nucleotide turnover. For SARS-CoV-2, this includes nsp7/[nsp8](#)/nsp12 as an RNA-dependent RNA polymerase; nsp13 as a helicase; nsp10/nsp14 as an 3'-to-5' exonuclease complex; nsp15 as an endoribonuclease and nsp16 as a 2'-O-ribose methyltransferase.

[Remdesivir](#) (currently in clinical trials to treat COVID-19), is described as a non-selective inhibitor of multiple RNA viruses, and has shown some efficacy in MERS-CoV and SARS-CoV infection of monkeys (de Wit *et al.*, 2020). In *in vitro* investigations, the triphosphate analogue of remdesivir inhibited RNA

synthesis of MERS-CoV RNA-dependent RNA polymerase (primarily nsp8/nsp12 complexes derived from co-expression in insect cells of a construct containing nsp5, nsp7, nsp8 and nsp12) with an IC<sub>50</sub> value of 32 nM when nucleotide levels were low, increasing to 690 nM at higher nucleotide concentrations (Gordon *et al.*, 2020a). *In silico* modelling identified that remdesivir, as well as the approved antiviral drugs [ribavirin](#), [sofosbuvir](#) and tenofovir could bind tightly to the active site of nsp12 from SARS-CoV-2, based on the crystal structure of SARS-CoV (Elfiky, 2020).

However, ribavirin alone had no significant effect in a clinical trial with SARS patients, although a combination of ribavirin with lopinavir-ritonavir and corticosterone had lower rating of ARDS and death (for review, see Zumla *et al.*, 2016). In-depth analysis has not been completed with MERS patients, although an ongoing Phase 2 clinical trial for MERS uses a combination therapy of lopinavir/ritonavir and interferon  $\beta$ 1b (Arabi *et al.*, 2020).

Nsp13 is a helicase, which enables unwinding of duplex RNA. The exoribonuclease activity of nsp14 sets the coronaviruses apart (Snijder *et al.*, 2003), as the enzyme is suggested to remove damaging mutations from the genome (Eckerle *et al.*, 2010; Sevajol *et al.*, 2014). In other coronaviruses, the endoribonuclease nsp15 has some selectivity for hydrolysing polyU sequences (Hackbart *et al.*, 2020). This enables the virus to delay or minimise initiation of the innate immune system by hydrolysing negative sense polyU nucleotides, which activate the MDA5 system to evoke interferon production (discussed further below). Nsp16 is a methyltransferase, which uses S-adenosyl-L-methionine as a co-substrate to assist in cap formation (Decroly *et al.*, 2008).

#### Protein: protein interactions in recombinant expression

In a preliminary (not yet peer reviewed) report, a series of tagged recombinant proteins from SARS-CoV-2 were expressed in HEK293 cells and then protein partners were identified by affinity purification/mass spectrometry (Gordon *et al.*, 2020b). For nsp12 (RNA-dependent RNA polymerase) and nsp14 (3'-5'-exonuclease) of SARS-CoV-2, interactions with receptor interacting protein kinase 1 ([RIPK1](#)) and inosine monophosphate dehydrogenase 2 ([IMPDH2](#)), respectively, were identified. For these two targets, there are established approved drugs. Thus, [ponatinib](#), which is used to treat acute myelogenous leukemia or chronic myelogenous leukemia (Philadelphia chromosome), targets multiple protein kinases, inhibiting RIPK1 with an IC<sub>50</sub> value of 12 nM (Najjar *et al.*, 2015). [Mycophenolic acid](#) and [ribavirin](#) are IMPDH2 inhibitors with IC<sub>50</sub> values of 20 nM (Nelson *et al.*, 1990) and 1-3  $\mu$ M (Wittine *et al.*, 2012) ranges, respectively, with clinical uses in organ transplantation and antiviral therapy, respectively.

Reservations about the use of ribavirin have already been noted above. Mycophenolic acid as a monotherapy was examined in a MER-CoV-infected non-human primate model, where the authors concluded it actually worsened the condition (Chan *et al.*, 2015).

Nsp13 (helicase) and nsp15 (endoribonuclease) have been described to bind to centrosome-associated protein 250 ([CEP250](#)) and RNF41 (also known as NRDP1, [Link to UniProt](#)), respectively, in a preliminary report of recombinant expression (Gordon *et al.*, 2020b). CEP250 is suggested to influence centrosome cohesion during interphase (de Castro-Miro *et al.*, 2016) and to be elevated in peripheral T cell lymphomas (Cooper *et al.*, 2011). The functional relevance of nsp13 interaction with CEP250 is not yet clear. RNF41 is an E3 ubiquitin ligase, which polyubiquitinates myeloid differentiating primary response gene 88 (MyD88, [link to UniProt](#)), an adaptor protein for [Toll-like receptors](#), which allows activation of TBK1 and IRF3 (see below) and thereby increases type I interferon production (Wang *et al.*, 2009).

#### Targeting phospholipid turnover

The lipid profile of viruses appears to be important in terms of viral entry into the cell, either as sites for anchoring or for endocytosis (for review, see Heaton and Randall, 2011; Mazzon and Mercer, 2014). Replication of SARS-CoV is reported to take place associated with the endoplasmic reticulum in 'replicative organelles' incorporating convoluted membranes and interconnected double-membrane vesicles, inferring a capacity for the virus to induce extensive reorganization of intracellular phospholipid membranes (Knoops *et al.*, 2008). Three non-structural proteins from



SARS-CoV with transmembrane domains, nsp3 PL<sub>pro</sub> (see above), nsp4 and [nsp6](#) when co-expressed in model cells prompted the formation of these double-membrane vesicles (Angelini *et al.*, 2013), although it is unclear whether specific catalytic activities are necessary for this action.

The lipidome of influenza virus (also a positive strand RNA virus) consists of glycerophospholipids, sterols (mainly cholesterol) and sphingolipids, with sphingolipids and cholesterol enriched compared to the host cell membrane (Gerl *et al.*, 2012), but there does not yet appear to be a parallel investigation of SARS-CoV.

[Cytosolic phospholipase A<sub>2α</sub>](#), cPLA<sub>2α</sub>, hydrolyses phospholipid to produce lysophospholipids and free fatty acids. Using alphacoronavirus HCoV-229E-infected Huh-7 cells, inhibition of cPLA<sub>2α</sub> using pyrrolidine-2 at higher concentrations (20 μM) evoked an inhibition of viral titre (Muller *et al.*, 2018). [Arachidonoyl trifluoromethylketone](#), a non-selective inhibitor of multiple eicosanoid-metabolising enzymes including PLA<sub>2</sub> isoforms, also inhibited viral titres at higher concentrations (Muller *et al.*, 2018). Transmission electron microscopy suggested that cPLA<sub>2α</sub> inhibition reduced the density of double-membrane vesicles (Muller *et al.*, 2018). Analysis of lipid metabolites indicated that HCoV-229E-infected Huh-7 cells showed increases in levels of ceramides, lysophospholipids and phosphatidylglycerols, with decreases in phosphatidic acids (Muller *et al.*, 2018). 20 μM pyrrolidine-2 inhibited the elevations in lysophospholipids and phosphatidylglycerols, but not the ceramides. Intriguingly, some selectivity of the involvement of PLA<sub>2α</sub> was suggested as pyrrolidine-2 also displayed antiviral activities against other members of the *Coronaviridae* (and *Togaviridae*) families, while members of the *Picornaviridae* family were not affected.

Although speculative, there is the possibility that some of the benefits of glucocorticoid administration in the clinic might be the up-regulation of annexins, and the subsequent binding and concealment of membrane phospholipid from further metabolism (for review, see Lemmon, 2008). While clearly some distance from a validated target, since phospholipids are an essential component of enveloped viral proliferation, targeting the host availability of key structural lipids, particularly sphingolipids, has been proposed to be a useful strategy in preventing propagation of enveloped human RNA viruses, including influenza, HIV and hepatitis C (Yager and Konan, 2019). Currently, however, assays to screen inhibitors of cPLA<sub>2α</sub> are relatively limited.

#### [Targetting carbohydrate turnover](#)

Given that a number of the viral proteins, including the two structural proteins Spike and Membrane, are glycoproteins, there is clearly a diversion of sugars from the host. It is unclear as yet, whether specific sugars are involved and whether specific host glycosyltransferases are involved in the processing of coronavirus glycoproteins and might, therefore, form further tractable targets for drug discovery. Notably, in studies using site-directed mutagenesis of the Spike protein from SARS-CoV, glycosylation was identified at three glutamine residues within the S1 region, with no loss of binding to ACE2-expressing cell of mutated (non-glycosylated) fragments (Chakraborti *et al.*, 2005).

### [The other viral structural proteins](#)

#### [The E envelope protein](#)

The Envelope proteins of SARS-CoV, HCoV229E and MERS are small (<100 aa) single transmembrane domain proteins (see **Figure 2**) and constitute ion channels with selectivity for monovalent cations over monovalent anions (Wilson *et al.*, 2004; Zhang *et al.*, 2014) apparently forming homopentamers in model membranes (Pervushin *et al.*, 2009; Surya *et al.*, 2015). Infecting or transfecting the coronavirus E message into cells results in accumulation of protein in the Golgi region (Ruch and Machamer, 2012). Conserved cys residues proximal to the transmembrane domain internally within the virus are palmitoylated (Lopez *et al.*, 2008), a post-translational modification suggested to allow an internal inflexion point in the protein (Ruch and Machamer, 2012).

[Hexamethylene-amiloride](#) has been described as an inhibitor of the HIV-1 virus Vpu ion channel (Ewart *et al.*, 2002) and to reduce virus proliferation in human macrophages in culture (Ewart *et al.*, 2004). Hexamethylene-amiloride, but not the clinically-used [amiloride](#), inhibited the SARS-CoV



envelope protein-associated ion channel activity when expressed in HEK293 cells (Pervushin *et al.*, 2009).

[Amantadine](#) has had multiple uses clinically, including in the therapy of Parkinson's disease (for review, see Vanle *et al.*, 2018). It has been used to treat influenza A infection through targeting the M2 ion channel (Pinto *et al.*, 1992; Wang *et al.*, 1993; Holsinger *et al.*, 1994), although it is no longer recommended in the UK or US because of drug resistance (for review, see Li *et al.*, 2015).

Amantadine at higher concentrations (100  $\mu$ M) was found to inhibit the SARS-CoV E protein expressed in model membranes (Torres *et al.*, 2007).

SARS-CoV E protein was identified as being pro-apoptotic upon transfection into Vero E6 monkey epithelial cells, where it localized to both plasma membrane and punctate cytoplasmic locations (Chan *et al.*, 2009). Indeed, the SARS-CoV E protein's ion channel function has been linked to calcium entry into endoplasmic reticulum/Golgi membrane complexes and the subsequent activation of the [NLRP3](#) inflammasome, leading to interleukin- $\beta$  ([IL-1 \$\beta\$](#) ) production (Nieto-Torres *et al.*, 2015).

siRNA targeting of the Envelope protein of SARS-CoV reduced virus release in culture media, without altering N and P gene expression in FRhK-4 monkey kidney epithelial cells (Lu *et al.*, 2006). A similar observation was reported for the ORF4a protein (derived from the *Orf4a* gene) of HCoV229E (Zhang *et al.*, 2014). Infecting mice with SARS-CoV in which the E protein ion channel function was disrupted showed unchanged viral proliferation but reduced IL-1 $\beta$  and oedema levels in the lungs and better survival over 10 days post-infection (Nieto-Torres *et al.*, 2014).

In a preliminary (as yet, unreviewed) report, the E protein of SARS-CoV-2 has been reported to interact with [BRD2/BRD4 BET family bromodomain kinases](#) when expressed in HEK293 cells (Gordon *et al.*, 2020b). [JQ1](#) and [RVX208](#) are BRD2/4 inhibitors with IC<sub>50</sub> values with 40-120 and 50-1800 nM ranges, respectively.

#### [The M membrane protein](#)

The membrane protein is usually regarded as the most abundant protein in the coronavirus envelope (see **Figure 2**) and is of intermediate size in SARS-CoV-2 (222 aa). It is thought to assist in viral assembly by collating the other surface structural proteins (Ruch and Machamer, 2012).

#### [The N nucleocapsid phosphoprotein](#)

The N protein is of moderate size in SARS-CoV-2 (419 aa), highly basic and binds the viral RNA as a dimeric entity (Fan *et al.*, 2005) into nucleocapsids (see **Figure 2**), which afford protection for the viral genome, while also providing access for replication at appropriate times (for review, see McBride *et al.*, 2014). In a preliminary (not yet peer reviewed) report, the N protein of SARS-CoV-2 was tagged and expressed in HEK293 cells and then protein partners were identified by affinity purification/mass spectrometry (Gordon *et al.*, 2020b). The N protein was suggested to interact with casein kinase 2 ([CK2](#)), La-related protein 1 (LARP1, [Link to UniProt](#)) and stress granule protein Ras GTPase-activating protein-binding protein 1 (G3BP1, [Link to UniProt](#)). CK2 phosphorylates a broad range of cellular targets, mostly in the nucleus, to regulate development and differentiation (for review, see Gotz and Montenarh, 2017). Although not in use clinically, two inhibitors are described to target CK2 with high affinity. [Silmitasertib](#) is a CK2 inhibitor with an IC<sub>50</sub> value of 1 nM (Pierre *et al.*, 2011), while [TMCB](#) has a K<sub>i</sub> value of 21 nM (Janeczko *et al.*, 2012). LARP1 is an RNA-binding protein, which releases RNA when phosphorylated by mTORC1 (Fonseca *et al.*, 2015; Hong *et al.*, 2017). LARP1 seems to preferentially bind 5'-terminal oligopyrimidines with an as-yet unclear cellular role (Philippe *et al.*, 2020). Of the three targets suggested to associate with SARS-CoV-2 N phosphoprotein, G3BP1 seems a relevant focus for therapy against COVID-19. G3BP1 regulates the innate immune response (Kim *et al.*, 2019; Liu *et al.*, 2019; Wiser *et al.*, 2019; Yang *et al.*, 2019) and stress granules reduce the replication of MERS-CoV (Nakagawa *et al.*, 2018), so there is a potential for targeted drug discovery.

#### [Interactions with the host innate immune system](#)

SARS-CoV produces proteins that interfere with interferon pathways (nsp1, nsp3, nsp16, ORF3b, ORF6, [ORF9b](#), M and N proteins, Wong *et al.*, 2016) and NLRP3 inflammasome activators (E, [ORF3a](#), ORF8b) which are closely related to orthologues found in SARS-CoV-2. Fung *et al* (2020) have recently reviewed the molecular aspects whereby SARS-CoV and, by inference, SARS-CoV-2, evades immune surveillance, activates the inflammasome and causes pyroptosis. Other coronaviruses may give an indication as to how this is happening. HCoV-229E rapidly kills dendritic cells, while monocytes are much more resistant. The rapid invasion of, and replication in, dendritic cells kills them within a few hours of infection (Mesel-Lemoine *et al.*, 2012). Dendritic cells are sentinel cells in the respiratory tract, and plasmacytoid dendritic cells are a crucial antiviral defence via interferon production, and by modifying antibody production. Thus, these viruses can impair control of viral dissemination and the formation of long-lasting immune memory. Penetration of SARS-CoV-2 infection deep into the lungs, and eventually the alveolae, results in the ‘cytokine storm’ which accompanies pneumonia and lung fibrosis and is probably a major determinant of the necessity for intubation, and also mortality (Shi *et al.*, 2020b). It is currently not known what specific factor/s differentiate the patients who develop this; although mortality among younger health workers may indicate that initial viral load may play a role. Immunological agents which can prevent or control the ‘cytokine storm’ could therefore have a major effect on necessity to intubate and mortality. [Tocilizumab](#) is a monoclonal antibody targeting [interleukin-6 receptors](#), as a means to interfere with the effects of chronic autoimmune disorders such as rheumatoid arthritis. The Chinese Clinical Trials Registry has two studies that are designed to evaluate tocilizumab efficacy in patients with severe COVID-19 pneumonia (Registration Numbers [ChiCTR2000029765](#) and [ChiCTR2000030442](#)). Similarly, [anakinra](#), which is a slightly modified version of an endogenous antagonist of [interleukin-1 receptors](#), is being investigated in clinical trials in multiple locations in patients with COVID-19 infection ([NCT04324021](#), [NCT04330638](#) and [NCT02735707](#)).

It has been reported that in stage III of COVID-19, a critical point with a high viral load and severe respiratory involvement, lungs of patients appear with ‘ground-glass’ patches in CT scans, while autopsy reports indicate that the lungs are filled with a ‘clear liquid jelly’ (Shi *et al.*, 2020c; Xu *et al.*, 2020), similar to an observation in drowning victims. On the hypothesis that inflammation-driven [hyaluronan](#) production (via hyaluronan synthase 2, HAS2, [Link to UniProt](#)), and associated water retention may be critical; a recent study proposed therapy via administration of recombinant hyaluronidase or inhibitors of HAS2 (Shi *et al.*, 2020c).

The interaction between the virus and the innate immune system is complex and multifactorial, with temporal intricacies. It is beyond the scope of this review to identify all the multiple components and so we discuss here those pathways we consider most tractable.

#### [Viral nucleotides and MDA5/MAVS/Interferon production](#)

The positive sense RNA of coronaviruses is translated to produce the replication machinery, which allows complementary negative sense RNA to be synthesised, which itself is the template for the synthesis of positive strand RNA. As a consequence, double-stranded RNA is produced, which act as a pathogen-associated molecular pattern (PAMP) targetting [MDA5](#) (interferon induced with helicase C domain 1, also known as melanoma differentiation antigen 5, Kato *et al.*, 2006) from the [RIG-1-like receptor family](#) of cytoplasmic pattern recognition receptors (for reviews, see Schlee, 2013; Bryant *et al.*, 2015). MDA5 differs from [RIG-1](#) (DexD/H-box helicase 58, also known as retinoic acid-inducible gene 1) in recognising longer dsRNA (Kato *et al.*, 2006; Goubau *et al.*, 2014), and it has been proposed this differentiates the sensing of positive-stranded viruses by MDA5 compared to negative strand virus sensing by RIG-I (Kato *et al.*, 2006; Goubau *et al.*, 2013). RIG-1-like receptors have an *N*-terminal caspase activation and recruitment domain (CARD), which shows ligand-dependent interaction with CARDS from other proteins, such as mitochondrial antiviral signalling protein (MAVS, [Link to UniProt](#)). MAVS activates [IKK family kinases](#), such as TANK binding kinase ([TBK1](#)) and [IKK-ε](#), leading to the phosphorylation of interferon regulatory factors, such as IRF3 ([Link to UniProt](#)) and IRF7 ([Link to UniProt](#)). This induces the transcription of Type I interferon genes, such as [interferon-β](#)

and CCL5 (also known as [RANTES](#)) (Doyle *et al.*, 2002; Fitzgerald *et al.*, 2003; Sharma *et al.*, 2003). MAVS present in peroxisomes is also able to recruit short-acting, interferon-independent defense factors (Dixit *et al.*, 2010).

The ORF9b protein from SARS-CoV has also been reported to target mitochondrial MAVS to limit the interferon response, as well as triggering proteolysis of dynamin-like protein 1 ([Link to UniProt](#)) thereby prompting the formation of mitochondria-associated autophagosomes claimed to create 'havoc' in energy production in infected cells (Shi *et al.*, 2014). In a preliminary (as yet, unreviewed) report, ORF9b of SARS-CoV-2 has been reported to interact with translocases of outer membrane 70 (Tom70, [Link to UniProt](#)) when expressed in HEK293 cells (Gordon *et al.*, 2020b). Tom70 activates mitochondrial IRF3 (Liu *et al.*, 2010) and so this is a potential locus for pharmacological intervention, but as yet with no inhibitors described in the literature.

A number of other coronavirus proteins have been identified to influence the IRF3 pathway to restrict interferon production. This includes the MERS-CoV PL<sub>pro</sub> proteinase (Yang *et al.*, 2014), as well as the ORF6 and Nucleocapsid proteins from SARS-CoV (Kopecky-Bromberg *et al.*, 2007). The ORF6 protein of SARS-CoV has also been described to reduce the activity of a series of karyopherin-dependent host transcription factors (Sims *et al.*, 2013). Karyopherin is an importin, which traffics proteins between the cytoplasm and the nucleus (for review, see Kosyna and Depping, 2018; Guo *et al.*, 2019).

~~Translocases of outer membrane 70 (Tom70, [Link to UniProt](#)) activates mitochondrial IRF3 (Liu *et al.*, 2010). The Orf9b protein of SARS-CoV-2 has been reported to interact with Tom70 when expressed in HEK293 cells (Gordon *et al.*, 2020b).~~

Clearly, the induction and suppression of interferon production are central to numerous human diseases and have been extensively studied; the 'trick' to treat COVID-19 will be to identify a novel angle for therapeutic exploitation.

## [nsp1](#)

Working with SARS-CoV (not SARS-CoV-2), Pfefferle and colleagues used yeast two-hybrid screens to identify interactions between the viral and human proteomes (Pfefferle *et al.*, 2011). They identified an interesting interaction between viral Nsp1 and a group of host peptidyl-prolyl *cis-trans*-isomerases (PPIA, PPIG, PPIH and FKBP1A, FKBP1B), all of which modulate the calcineurin/NFAT pathway important in immune activation (reviewed by Hogan *et al.*, 2003). The nsp1 protein acts on these to activate NFAT signalling and immune activation. [Cyclosporine A](#), an inhibitor of this pathway, has been used for several decades to control transplant rejection and some autoimmune diseases and, in a simple *in vitro* assay, cyclosporine inhibited SARS-CoV transcription/replication in (non-immune-system) cells (Pfefferle *et al.*, 2011). SARS-CoV-2 has an nsp1 protein closely related to that of SARS-CoV (Dong *et al.*, 2020; Srinivasan *et al.*, 2020), though its effect on the NFAT pathway seems not to have been reported. Nevertheless, cyclosporine has been shown to inhibit SARS-CoV2 in an *in vitro* Vero cell-based assay in a preliminary report (as yet not peer-reviewed, Jeon *et al.*, 2020). It has therefore been suggested as a drug target (see, for example, Li and De Clercq, 2020). It may seem paradoxical to suggest an inhibitor of immune activation as a treatment for viral disease, but for the subgroup of patients that might suffer cytokine storms (Mehta *et al.*, 2020), the double-action might be useful.

## [ORF3a, ORF6, ORF8 and other viral proteins](#)

The [ORF3a](#) protein of SARS-CoV appears to bind calcium in a cytoplasmic domain (Minakshi *et al.*, 2014) and to elicit a response from the innate immune system by enhancing the ubiquitination of apoptosis-associated speck-like protein containing a CARD (Asc, [Link to UniProt](#)), which in turn activates the [NLRP3](#) inflammasome and [caspase 1](#) (Siu *et al.*, 2019). The potential for targeting Asc and the NLRP3 inflammasome for therapeutic benefit in inflammatory conditions has recently been reviewed (Mangan *et al.*, 2018), although there are no inhibitors in the clinic as yet.

In SARS-CoV, the *Orf8a* and *Orf8b* genes became separated as the disease progressed by a 29-nucleotide deletion (Chinese SARS Molecular Epidemiology Consortium, 2004; Oostra *et al.*, 2007). The *Orf8a* gene of SARS-CoV encodes a short (31 aa, 1 TM, [Link to UniProt](#)) protein, which forms a cation channel of predicted pentameric structure (Chen *et al.*, 2011). In SARS-CoV-2 and a bat-derived coronavirus, in contrast to the SARS-CoV-2 genome, *Orf8* encodes a continuous 121 aa ORF8 protein (Cagliani *et al.*, 2020). Given that sequence analysis of different strains of SARS-CoV-2 suggests that the *Orf8* locus displays only limited evidence of positive selection (Cagliani *et al.*, 2020), it seems germane to investigate the profile of ORF8 protein in more depth. Sequence comparisons led to prediction of secondary structure composed of an  $\alpha$ -helix and a  $\beta$ -sheet containing six strands (Chan *et al.*, 2020), but there appears not to be any literature as to whether this entity is a functional ion channel.

In a preliminary (as yet, unreviewed) report, the ORF14 protein ([Link to UniProt](#)) of SARS-CoV-2 has been reported to interact with NOD-like receptor X1 ([NLRX1](#)), proteinase-activated receptor 2 ([PAR2/F2RL1](#)) and NEDD4 family-interacting protein 2 (NDFIP2, [impdh2 Link to UniProt](#)), among other proteins of the I $\kappa$ B/NF $\kappa$ B pathway, when expressed in HEK293 cells (Gordon *et al.*, 2020b). At the moment, there are no approved drugs targeting PAR2, although AZ3451 ([Link to GtoP](#)) acts as a negative allosteric modulator with pIC<sub>50</sub> values of 5-23 nM (Cheng *et al.*, 2017).

There is a limited insight into the roles or potential exploitability of the remaining range of other viral proteins (nsp2; nsp9; nsp11, proteins Orf3b; ORF6; [ORF7a](#); ORF7b; ORF10).

## Animal models of SARS-CoV-2 infection

The spike glycoproteins in SARS-CoV and MERS-CoV are crucial for host specificity and jumping between species, e.g. from bats to humans (Lu *et al.*, 2015), and from dromedary camels to humans (MERS-CoV) and also the recent cross-over of a HKU2-related coronavirus to pigs as a Swine Acute Diarrhoea Syndrome (SADS-CoV) (Zhou *et al.*, 2018). SADS-CoV appears to influence the innate immune system by reducing interferon- $\beta$  production evoked through IPS-1 and RIG-I pathways, but not through IRF3, TBK1 and IKK $\epsilon$  (Zhou *et al.*, 2020).

ACE2, as an anchoring point for the Spike glycoprotein, is present throughout the animal kingdom, but small structural differences are critical for interaction with the spike protein (Li *et al.*, 2020b; Luan *et al.*, 2020). Key sequences of the Spike protein from SARS-CoV and SARS-CoV-2 are responsible for binding to ACE2. Luan *et al.* (2020) found that the key residues in S protein, from SARS-CoV and SARS-CoV-2, recognised in ACE2 from dog, cat, pangolin and *Circetidae* mammals (simulated through homology modelling) were broadly similar. Mouse ACE2 is inefficient in prompting entry of both SARS-CoV and SARS-CoV-2 (Fung *et al.*, 2020). Cats and dogs suffer from their own specific coronavirus infections (e.g. canine respiratory coronavirus, feline coronavirus) without significant cross-over to humans. A preliminary (as yet lacking peer review) very recent report has suggested that cats and ferrets are sensitive to SARS-CoV-2, but dogs, pigs, chickens and ducks are much less sensitive (Shi *et al.*, 2020a). Ferrets, which have previously been used as models for respiratory tract infections, and retained the SARS-CoV-2 virus in the respiratory tract, while Shi *et al.* (2020) showed that the infection was transmitted between cats by aerosol (which may have implications for confinement); infected cats subsequently produced antibodies (Shi *et al.*, 2020a).

The Syrian hamster has been used as a model for SARS-CoV (Roberts *et al.*, 2005; Roberts *et al.*, 2006; de Wit *et al.*, 2013) and studies with mice and Syrian hamsters are ongoing with SARS-CoV-2. A preliminary report (as yet not peer-reviewed) suggests that monkeys can be infected and show signs of sickness similar to COVID-19, producing antibodies which minimize the signs of subsequent infection (-). In a small study where three juvenile (3-5 years old) and two mature (15 years old) rhesus macaques were infected intratracheally with the SARS-CoV-2 virus, all the monkeys showed symptoms of inflammation and interstitial pneumonia, with a greater apparent severity in the older animals (Yu *et al.*, 2020).

Thus, while there is intensive research in animal models, a clearly validated model is still not apparent.



## Inter-individual variations in susceptibility

Given the similarities in the viruses and their symptoms, there is clearly a value to comparing the profiles of sufferers from the original SARS and subsequent MERS outbreaks with COVID-19 to evaluate the risk factors associated with each event individually and collectively. A detailed consideration is beyond the scope of this review, but there are some obvious questions to ask (not in an order of priority).

1. What factor/s determine resistance to infection?  
It is apparent that many individuals who test positive for SARS-CoV-2 infection only experience 'mild' symptoms, others suffer a level of debilitation requiring hospitalization with limited supervision, and a third group require assisted breathing.
2. Is blood group a predictor?  
There is preliminary evidence (as yet, not peer-reviewed) suggesting that people with type A blood might be more at risk of COVID-19 than those with other blood types (Zhao *et al.*, 2020).
3. Are there 'simple' genetic markers which predict this variation?  
For example, are single nucleotide polymorphisms/haplotypes for key targets (including ACE2, TMPRSS2, etc, Delanghe *et al.*, 2020) associated with higher or lower damage in humans infected with SARS-CoV, MERS-CoV or SARS-CoV-2?
4. Reports suggest that there is a preponderance of male victims of COVID-19, for example in Spain (Instituto de Salud Carlos III, Ministry of Science & Innovation, Spain. [Retrieved](#) on 2020-03-25, referring to data from 2020-03-24). What might be the cause of this sexual divergence?
5. Is smoking history a predictor of variation?  
One potential explanation for the relatively high proportion of male victims has been suggested to be previous smoking history (Cai, 2020; Olds and Kabbani, 2020; Vardavas and Nikitara, 2020), clearly a general risk factor for many diseases. Is there evidence from the SARS and MERS outbreaks to suggest a commonality of susceptibility?
6. What is the impact of contracting the virus on individuals with other underlying conditions?  
For example, what are the mechanism/s underlying why some sufferers of hypertension and/or diabetes might be at higher risk (<https://www.immunopaedia.org.za/breaking-news/why-are-hypertension-and-diabetes-patients-at-high-risk-of-severe-covid-19/>)? Is there evidence that patients on ACE inhibitors or angiotensin receptor blockers were at higher risk with SARS-CoV and MERS-CoV infections and, currently, for SARS-CoV-2 infection?
7. How will the evolution of the virus alter rates of infection and the severity of symptoms?  
Some level of mutation is to be expected, and indeed has been noted for the SARS-CoV-2. At the moment, it is too early to identify the significance of any influence of these mutations on the course of COVID-19.

Some of these questions are more tractable since the SARS and MERS outbreaks because of the strides being made in sophisticated molecular biological techniques (e.g. NextGen Sequencing). An additional distinction compared to the previous outbreaks is the major increase in patient numbers associated with COVID-19, allowing greater comparisons to be made in many more geographical locations.

Inevitably other questions will form as greater detail becomes available.

## Conclusion and recommendations

This review has concentrated on the prevailing hypothesis that an essential first step in infection is SARS-CoV-2 binding to ACE2 and for TMPRSS2 to prime the viral Spike protein. We further hypothesise that both proteins must be expressed on a target cell for the virus to gain entry. TMPESS2 has an extensive cellular expression profile, whereas ACE2 is more limited and is usually at



low levels, unless increased by risk factors such being sex, age, and smoking history, so is likely to be rate-limiting. Other potential target proteins such as cathepsin L or B<sup>0</sup>AT1 may also prove important. Currently, although there are no drugs approved for the treatment of patients with COVID-19, the pandemic has triggered a stampede into clinical trials with both approved and investigational agents. The pharmacological rationale for these trials is sometimes obscure, but there is a logic to focus on viral entry and replication, as well as limiting the host immune response.

For the immediate term, the highest priority would be to investigate known antivirals to mitigate effects of COVID-19. For the longer term, a vaccine (for review, see Amanat and Krammer, 2020) seems to hold the most promise to reduce COVID-19 damage. There is also a role in the mid-term, however, for drug discovery conducted in mainstream pharmacology labs. The goal here would be an international co-ordinated approach to drug re-purposing; examining the spectrum of licensed drugs (likely to be less than 2000, varying dependent on jurisdictions). These would ideally be screened in a co-ordinated, blinded fashion in multiple labs simultaneously to account for any minor methodological differences. This requires the re-opening of screening and protein biosynthesis labs closed at the start of the pandemic, while ensuring that workers are kept safe.

If one were to write a Target Product Profile for a drug to treat COVID-19, several parallel profiles can be identified. There are clear considerations, which may be identified as desirable pharmacodynamic, screening methodologies, drug metabolism and pharmacokinetic and formulation profiles.

From a pharmacodynamic perspective, a priority would be to screen the proteinases identified in this review (ACE2, TMPRSS2, ADAM17, cathepsin L, cathepsin B, PL<sub>pro</sub> and 3CL<sub>pro</sub>). A second parallel stream would assess inhibitors of the viral RNA polymerase and endoribonuclease complexes, as well as the ion channel functions of the viral Envelope (and potentially the Orf8 protein). Clearly there are multiple other targets, which might bear fruit, and so further studies should assess the tractability of B<sup>0</sup>AT1/SLC6A19, B<sup>0</sup>AT3/SLC6A18, IMPDH2 and HAS2. Further, the molecular mechanism of action of [ivermectin](#) should be assessed, since it has recently been shown to inhibit *in vitro* SARS-CoV-2 replication (Caly *et al.*, 2020). This agent is used clinically as an anthelmintic, probably through blocking invertebrate glutamate receptors although it also inhibits mammalian glycine receptors and acts as a positive allosteric modulator of other mammalian ligand-gated ion channels.

From a screening aspect, biophysical and biochemical screens would probably take a matter of days-to-weeks. Following mass availability of the recombinant proteins involved, the capacity for inhibition should be assessed using a library of already approved drugs. Biophysical methods can be applied, such as surface plasmon resonance or biolayer interferometry, to monitor the affinity of interaction between host ACE2 and viral spike glycoprotein in the presence of these agents, as well as the relevant proteins where multimerization is critical, such as the trimeric Spike glycoprotein. Assessing the remainder of the targets would likely adopt standard, fluorescent-based pharmacological methodologies.

If the assay involves the use of viral proteins, the constructs should acknowledge the inevitable mutations which the viral genome has/will undergo.

An overarching priority for the *in vitro* screening would be to recognise and replicate, as much as possible, relevant features of the virus and its lifecycle. This would include post-translational modifications of the viral proteins, such as glycosylation of the Spike and Membrane proteins. Additionally, while the high throughput screens described above for identifying inhibitors associated with components of the viral entry system, such as ACE2, should be confirmed in more translational assays, such as have been described for HIV cell entry in an automatable format (Bradley *et al.*, 2004).

A desirable element would also be to minimise adverse effects on the cardiovascular and respiratory system, given the high incidence of damage described associated with those systems (Esler and

Esler, 2020; Li *et al.*, 2020a; Lippi *et al.*, 2020). Candidate drugs should also not increase activity of the IL-6 (or any other pro-inflammatory cytokine) pathway to avoid provoking a cytokine storm.

If a similar approach were taken to the ways in which targetted therapy is applied for certain types of cancer, there would be an increased benefit in a multimodal strategy. Thus, in cancers where EGF/EGF receptors are involved, it is possible to target the ligand using chelating antibodies, to antagonise the receptor using blocking antibodies, to use specific antibodies to prevent dimerization of the receptor and to inhibit the catalytic activity of the receptor with small molecular inhibitors. It should be possible to reproduce this approach by simultaneously targetting several steps in the viral cycle (while naturally being cognisant of the potential for phenomena of drug:drug interactions, for instance in terms of convergent pathways of drug metabolism). This approach, enacted for the treatment of hepatitis C and human immunodeficiency viruses, for example, should also show benefit in reducing the capacity for drug-driven mutation in the enzyme.


From a DMPK perspective, a beneficial profile for any agent would avoid drug:drug interactions by not converging on key metabolic enzymes and/or transporters. Ideally, a once-daily treatment regimen would be optimal, but if more frequent administration were needed, there is likely to be good patient adherence, given the public response to 'spatial distancing'. From a formulation perspective, prophylactic use or for treatment of mild symptoms, an orally-administered or inhaled formulation would be appropriate. For more severe cases, where breathing is significantly impaired, an inhaled aerosolised version may be difficult to administer effectively; in this circumstance, a soluble version to be applied intravenously is likely to be useful.

Micro-organisms, such as viruses and bacteria, continue to evolve to evade our immune systems and previous pandemics contributed to the decline and fall of civilizations. There is a widespread hope that the current pandemic will be controlled by the rapid development of a safe and efficacious vaccine. Clearly, there are major successes with vaccines targetting viral disease, but, to date no vaccine has been successfully produced to protect against human betacoronaviruses such as those causing SARS and MERS. On the contrary, multiple viral diseases have been successfully controlled by pharmacological agents. HIV-AIDS became more widespread in the last century and was associated with high morbidity and mortality. As a result of the discovery of novel pharmacological treatments, including specific antivirals, it is now a chronic condition and a cure has been effected in at least two individuals. Similarly, the highly variable hepatitis C virus has resisted vaccines, but can be treated with direct antiviral agents allowing elimination of the virus in a very high proportion of those treated. This gives us hope that the roadmap outlined in this review may provide some relief from COVID-19 (and indeed for viral threats yet to come).

## Legend to Figures

**Figure 1:** The SARS-CoV-2 life cycle.


The novel virus uses angiotensin converting enzyme 2 (ACE2) to attach to target cells, including epithelial and endothelial cells, particularly in the lungs. SARS-CoV-2 requires the camostat-sensitive serine proteinase TMPRSS2 to prime the Spike protein for fusion and internalization. Thereafter, host cellular processes are exploited for viral replication and release from the cell.



**Figure 1:** The SARS-CoV-2 life cycle.

ACE2 is also expressed in high levels in the GI tract where it is associated with B<sup>0</sup>AT1/SLC6A19 that actively transports neutral amino acids across the apical membrane of epithelial cells. The serine proteinase ADAM17, present on cell surfaces, cleaves ACE2 to release an ectodomain of ACE2, including the active site, the circulation. This circulating form of ACE2 may also bind SARS-CoV-2, but this complex is predicted not to internalize and therefore could be exploited as a beneficial viral decoy. Recombinant ACE2 (GSK2586881) has been tested in Phase 2 clinical trials for the potential treatment of acute respiratory distress syndrome but it is not yet established if the compound will reduce viral load by acting as a decoy.

**Figure 2:** a cartoon of the virus structure, identifying the four structural proteins and the viral genome.



This Photo by Unknown Author is licensed under [CC BY-SA](#)  
PLEASE REDRAW

**Figure 2:** a cartoon of the virus structure, identifying the four structural proteins and the viral genome.

## Acknowledgements

We would like to thank our colleagues in the Universities of Cambridge, Edinburgh and Nottingham for helpful discussions and Wellcome Trust 107715/Z/15/Z (to A.P.D., J.J.M.).

## 982 Literature

- 983 Afar DE, Vivanco I, Hubert RS, Kuo J, Chen E *et al.* (2001). Catalytic cleavage of the androgen-  
 984 regulated TMPRSS2 protease results in its secretion by prostate and prostate cancer  
 985 epithelia. *Cancer Res* **61**: 1686-92 <https://www.ncbi.nlm.nih.gov/pubmed/11245484>
- 986 Alexander SPH, Kelly E, Mathie A, Peters JA, Veale EL *et al.* (2019). THE CONCISE GUIDE TO  
 987 PHARMACOLOGY 2019/20: Introduction and Other Protein Targets. *Br J Pharmacol* **176**  
 988 **Suppl 1**: S1-S20 <https://www.ncbi.nlm.nih.gov/pubmed/31710719>
- 989 Amanat F and Krammer F (2020). SARS-CoV-2 Vaccines: Status Report. *Immunity* **52**: 583-589  
 990 <https://www.ncbi.nlm.nih.gov/pubmed/32259480>
- 991 Anand K, Ziebuhr J, Wadhwani P, Mesters JR and Hilgenfeld R (2003). Coronavirus main proteinase  
 992 (3CL<sup>pro</sup>) structure: basis for design of anti-SARS drugs. *Science* **300**: 1763-7  
 993 <https://www.ncbi.nlm.nih.gov/pubmed/12746549>
- 994 Angeletti S, Benvenuto D, Bianchi M, Giovanetti M, Pascarella S *et al.* (2020). COVID-2019: The role  
 995 of the nsp2 and nsp3 in its pathogenesis. *J Med Virol*  
 996 <https://www.ncbi.nlm.nih.gov/pubmed/32083328>
- 997 Angelini MM, Akhlaghpour M, Neuman BW and Buchmeier MJ (2013). Severe acute respiratory  
 998 syndrome coronavirus nonstructural proteins 3, 4, and 6 induce double-membrane vesicles.  
 999 *mBio* **4**: <https://www.ncbi.nlm.nih.gov/pubmed/23943763>
- 1000 Arabi YM, Asiri AY, Assiri AM, Aziz Jokhdar HA, Alothman A *et al.* (2020). Treatment of Middle East  
 1001 respiratory syndrome with a combination of lopinavir/ritonavir and interferon-β1b  
 1002 (MIRACLE trial): statistical analysis plan for a recursive two-stage group sequential  
 1003 randomized controlled trial. *Trials* **21**: 8 <https://www.ncbi.nlm.nih.gov/pubmed/31900204>
- 1004 Baez-Santos YM, Mielech AM, Deng X, Baker S and Mesecar AD (2014). Catalytic function and  
 1005 substrate specificity of the papain-like protease domain of nsp3 from the Middle East  
 1006 respiratory syndrome coronavirus. *J Virol* **88**: 12511-27  
 1007 <https://www.ncbi.nlm.nih.gov/pubmed/25142582>
- 1008 Baez-Santos YM, St John SE and Mesecar AD (2015). The SARS-coronavirus papain-like protease:  
 1009 structure, function and inhibition by designed antiviral compounds. *Antiviral Res* **115**: 21-38  
 1010 <https://www.ncbi.nlm.nih.gov/pubmed/25554382>
- 1011 Barretto N, Jukneliene D, Ratia K, Chen Z, Mesecar AD *et al.* (2005). The papain-like protease of  
 1012 severe acute respiratory syndrome coronavirus has deubiquitinating activity. *J Virol* **79**:  
 1013 15189-98 <https://www.ncbi.nlm.nih.gov/pubmed/16306590>
- 1014 Batlle D, Wysocki J and Satchell K (2020). Soluble angiotensin-converting enzyme 2: a potential  
 1015 approach for coronavirus infection therapy? *Clin Sci (Lond)* **134**: 543-545  
 1016 <https://www.ncbi.nlm.nih.gov/pubmed/32167153>
- 1017 Belouzard S, Chu VC and Whittaker GR (2009). Activation of the SARS coronavirus spike protein via  
 1018 sequential proteolytic cleavage at two distinct sites. *Proc Natl Acad Sci U S A* **106**: 5871-6  
 1019 <https://www.ncbi.nlm.nih.gov/pubmed/19321428>
- 1020 Belouzard S, Millet JK, Licitra BN and Whittaker GR (2012). Mechanisms of coronavirus cell entry  
 1021 mediated by the viral spike protein. *Viruses* **4**: 1011-33  
 1022 <https://www.ncbi.nlm.nih.gov/pubmed/22816037>
- 1023 Benjafeld AV, Wang WY and Morris BJ (2004). No association of angiotensin-converting enzyme 2  
 1024 gene (ACE2) polymorphisms with essential hypertension. *Am J Hypertens* **17**: 624-8  
 1025 <https://www.ncbi.nlm.nih.gov/pubmed/15233982>
- 1026 Bennion DM, Rosado CA, Haltigan EA, Regenhardt RW, Sumners C *et al.* (2016). Serum activity of  
 1027 angiotensin converting enzyme 2 is decreased in patients with acute ischemic stroke. *J Renin*  
 1028 *Angiotensin Aldosterone Syst* **17**: <https://www.ncbi.nlm.nih.gov/pubmed/27488276>



1029 Bertram S, Heurich A, Lavender H, Gierer S, Danisch S *et al.* (2012). Influenza and SARS-coronavirus  
 1030 activating proteases TMPRSS2 and HAT are expressed at multiple sites in human respiratory  
 1031 and gastrointestinal tracts. *PLoS One* **7**: e35876  
 1032 <https://www.ncbi.nlm.nih.gov/pubmed/22558251>  
 1033 Bloch EM, Shoham S, Casadevall A, Sachais BS, Shaz B *et al.* (2020). Deployment of convalescent  
 1034 plasma for the prevention and treatment of COVID-19. *J Clin Invest*  
 1035 <https://www.ncbi.nlm.nih.gov/pubmed/32254064>  
 1036 Bradley J, Gill J, Bertelli F, Letafat S, Corbau R *et al.* (2004). Development and automation of a 384-  
 1037 well cell fusion assay to identify inhibitors of CCR5/CD4-mediated HIV virus entry. *J Biomol*  
 1038 *Screen* **9**: 516-24 <https://www.ncbi.nlm.nih.gov/pubmed/15452338>  
 1039 Bradner JE, West N, Grachan ML, Greenberg EF, Haggarty SJ *et al.* (2010). Chemical phylogenetics of  
 1040 histone deacetylases. *Nat Chem Biol* **6**: 238-243  
 1041 <https://www.ncbi.nlm.nih.gov/pubmed/20139990>  
 1042 Broer S and Gether U (2012). The solute carrier 6 family of transporters. *Br J Pharmacol* **167**: 256-78  
 1043 <https://www.ncbi.nlm.nih.gov/pubmed/22519513>  
 1044 Bryant CE, Orr S, Ferguson B, Symmons MF, Boyle JP *et al.* (2015). International Union of Basic and  
 1045 Clinical Pharmacology. XCVI. Pattern recognition receptors in health and disease. *Pharmacol*  
 1046 *Rev* **67**: 462-504 <https://www.ncbi.nlm.nih.gov/pubmed/25829385>  
 1047 Cagliani R, Forni D, Clerici M and Sironi M (2020). Computational inference of selection underlying  
 1048 the evolution of the novel coronavirus, SARS-CoV-2. *J Virol*  
 1049 <https://www.ncbi.nlm.nih.gov/pubmed/32238584>  
 1050 Cai H (2020). Sex difference and smoking predisposition in patients with COVID-19. *Lancet Respir*  
 1051 *Med* **8**: e20 <https://www.ncbi.nlm.nih.gov/pubmed/32171067>  
 1052 Caly L, Druce JD, Catton MG, Jans DA and Wagstaff KM (2020). The FDA-approved drug ivermectin  
 1053 inhibits the replication of SARS-CoV-2 in vitro. *Antiviral Res* **178**: 104787  
 1054 <https://www.ncbi.nlm.nih.gov/pubmed/32251768>  
 1055 Camargo SM, Singer D, Makrides V, Huggel K, Pos KM *et al.* (2009). Tissue-specific amino acid  
 1056 transporter partners ACE2 and collectrin differentially interact with hartnup mutations.  
 1057 *Gastroenterology* **136**: 872-82 <https://www.ncbi.nlm.nih.gov/pubmed/19185582>  
 1058 Chakraborti S, Prabakaran P, Xiao X and Dimitrov DS (2005). The SARS coronavirus S glycoprotein  
 1059 receptor binding domain: fine mapping and functional characterization. *Viol J* **2**: 73  
 1060 <https://www.ncbi.nlm.nih.gov/pubmed/16122388>  
 1061 Chan CM, Tsoi H, Chan WM, Zhai S, Wong CO *et al.* (2009). The ion channel activity of the SARS-  
 1062 coronavirus 3a protein is linked to its pro-apoptotic function. *Int J Biochem Cell Biol* **41**:  
 1063 2232-9 <https://www.ncbi.nlm.nih.gov/pubmed/19398035>  
 1064 Chan JF, Yao Y, Yeung ML, Deng W, Bao L *et al.* (2015). Treatment With Lopinavir/Ritonavir or  
 1065 Interferon-beta1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model  
 1066 of Common Marmoset. *J Infect Dis* **212**: 1904-13  
 1067 <https://www.ncbi.nlm.nih.gov/pubmed/26198719>  
 1068 Chan JF, Kok KH, Zhu Z, Chu H, To KK *et al.* (2020). Genomic characterization of the 2019 novel  
 1069 human-pathogenic coronavirus isolated from a patient with atypical pneumonia after  
 1070 visiting Wuhan. *Emerg Microbes Infect* **9**: 221-236  
 1071 <https://www.ncbi.nlm.nih.gov/pubmed/31987001>  
 1072 Chen CC, Kruger J, Sramala I, Hsu HJ, Henklein P *et al.* (2011). ORF8a of SARS-CoV forms an ion  
 1073 channel: experiments and molecular dynamics simulations. *Biochim Biophys Acta* **1808**: 572-  
 1074 9 <https://www.ncbi.nlm.nih.gov/pubmed/20708597>  
 1075 Chen Y, Savinov SN, Mielech AM, Cao T, Baker SC *et al.* (2015). X-ray Structural and Functional  
 1076 Studies of the Three Tandemly Linked Domains of Non-structural Protein 3 (nsp3) from

1077 Murine Hepatitis Virus Reveal Conserved Functions. *J Biol Chem* **290**: 25293-306  
 1078 <https://www.ncbi.nlm.nih.gov/pubmed/26296883>  
 1079 Chen YW, Lee MS, Lucht A, Chou FP, Huang W *et al.* (2010). TMPRSS2, a serine protease expressed in  
 1080 the prostate on the apical surface of luminal epithelial cells and released into semen in  
 1081 prostasomes, is misregulated in prostate cancer cells. *Am J Pathol* **176**: 2986-96  
 1082 <https://www.ncbi.nlm.nih.gov/pubmed/20382709>  
 1083 Chen YW, Yiu CB and Wong KY (2020). Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease  
 1084 (3CL (pro)) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug  
 1085 repurposing candidates. *F1000Res* **9**: 129 <https://www.ncbi.nlm.nih.gov/pubmed/32194944>  
 1086 Chen Z, Song X, Li Q, Xie L, Guo T *et al.* (2019). Androgen Receptor-Activated Enhancers  
 1087 Simultaneously Regulate Oncogene TMPRSS2 and lncRNA PRCAT38 in Prostate Cancer. *Cells*  
 1088 **8**: <https://www.ncbi.nlm.nih.gov/pubmed/31405024>  
 1089 Cheng RKY, Fiez-Vandal C, Schlenker O, Edman K, Aggeler B *et al.* (2017). Structural insight into  
 1090 allosteric modulation of protease-activated receptor 2. *Nature* **545**: 112-115  
 1091 <https://www.ncbi.nlm.nih.gov/pubmed/28445455>  
 1092 Chiu RW, Tang NL, Hui DS, Chung GT, Chim SS *et al.* (2004). ACE2 gene polymorphisms do not affect  
 1093 outcome of severe acute respiratory syndrome. *Clin Chem* **50**: 1683-6  
 1094 <https://www.ncbi.nlm.nih.gov/pubmed/15331509>  
 1095 Consortium CSME (2004). Molecular evolution of the SARS coronavirus during the course of the SARS  
 1096 epidemic in China. *Science* **303**: 1666-9 <https://www.ncbi.nlm.nih.gov/pubmed/14752165>  
 1097 Cooper CD, Lawrie CH, Liggins AP, Collins GP, Hatton CS *et al.* (2011). Identification and  
 1098 characterization of peripheral T-cell lymphoma-associated SEREX antigens. *PLoS One* **6**:  
 1099 e23916 <https://www.ncbi.nlm.nih.gov/pubmed/21887344>  
 1100 Corman VM, Muth D, Niemeyer D and Drosten C (2018). Hosts and Sources of Endemic Human  
 1101 Coronaviruses. *Adv Virus Res* **100**: 163-188  
 1102 <https://www.ncbi.nlm.nih.gov/pubmed/29551135>  
 1103 Crackower MA, Sarao R, Oudit GY, Yagil C, Kozieradzki I *et al.* (2002). Angiotensin-converting enzyme  
 1104 2 is an essential regulator of heart function. *Nature* **417**: 822-8  
 1105 <https://www.ncbi.nlm.nih.gov/pubmed/12075344>  
 1106 Cui J, Li F and Shi ZL (2019). Origin and evolution of pathogenic coronaviruses. *Nat Rev Microbiol* **17**:  
 1107 181-192 <https://www.ncbi.nlm.nih.gov/pubmed/30531947>  
 1108 Danthi SJ, Liang B, Smicker O, Coupland B, Gregory J *et al.* (2019). Identification and Characterization  
 1109 of Inhibitors of a Neutral Amino Acid Transporter, SLC6A19, Using Two Functional Cell-Based  
 1110 Assays. *SLAS Discov* **24**: 111-120 <https://www.ncbi.nlm.nih.gov/pubmed/30589598>  
 1111 Davenport AP, Scully CCG, de Graaf C, Brown AJH and Maguire JJ (2020). Advances in therapeutic  
 1112 peptides targeting G protein-coupled receptors. *Nature Reviews Drug Discovery*  
 1113 de Castro-Miro M, Tonda R, Escudero-Ferruz P, Andres R, Mayor-Lorenzo A *et al.* (2016). Novel  
 1114 Candidate Genes and a Wide Spectrum of Structural and Point Mutations Responsible for  
 1115 Inherited Retinal Dystrophies Revealed by Exome Sequencing. *PLoS One* **11**: e0168966  
 1116 <https://www.ncbi.nlm.nih.gov/pubmed/28005958>  
 1117 de Haan CA and Rottier PJ (2005). Molecular interactions in the assembly of coronaviruses. *Adv Virus*  
 1118 *Res* **64**: 165-230 <https://www.ncbi.nlm.nih.gov/pubmed/16139595>  
 1119 de Wit E, Prescott J, Baseler L, Bushmaker T, Thomas T *et al.* (2013). The Middle East respiratory  
 1120 syndrome coronavirus (MERS-CoV) does not replicate in Syrian hamsters. *PLoS One* **8**:  
 1121 e69127 <https://www.ncbi.nlm.nih.gov/pubmed/23844250>  
 1122 de Wit E, van Doremalen N, Falzarano D and Munster VJ (2016). SARS and MERS: recent insights into  
 1123 emerging coronaviruses. *Nat Rev Microbiol* **14**: 523-34  
 1124 <https://www.ncbi.nlm.nih.gov/pubmed/27344959>

1125 de Wit E, Feldmann F, Cronin J, Jordan R, Okumura A *et al.* (2020). Prophylactic and therapeutic  
1126 remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. *Proc*  
1127 *Natl Acad Sci U S A* **117**: 6771-6776 <https://www.ncbi.nlm.nih.gov/pubmed/32054787>

1128 Decroly E, Imbert I, Coutard B, Bouvet M, Selisko B *et al.* (2008). Coronavirus nonstructural protein  
1129 16 is a cap-0 binding enzyme possessing (nucleoside-2'O)-methyltransferase activity. *J Virol*  
1130 **82**: 8071-84 <https://www.ncbi.nlm.nih.gov/pubmed/18417574>

1131 Delanghe JR, Speeckaert MM and De Buyzere ML (2020). The host's angiotensin-converting enzyme  
1132 polymorphism may explain epidemiological findings in COVID-19 infections. *Clin Chim Acta*  
1133 **505**: 192-193 <https://www.ncbi.nlm.nih.gov/pubmed/32220422>

1134 Desforages M, Le Coupanec A, Dubeau P, Bourgouin A, Lajoie L *et al.* (2019). Human Coronaviruses  
1135 and Other Respiratory Viruses: Underestimated Opportunistic Pathogens of the Central  
1136 Nervous System? *Viruses* **12**: <https://www.ncbi.nlm.nih.gov/pubmed/31861926>

1137 Dixit E, Boulant S, Zhang Y, Lee AS, Odendall C *et al.* (2010). Peroxisomes are signaling platforms for  
1138 antiviral innate immunity. *Cell* **141**: 668-81  
1139 <https://www.ncbi.nlm.nih.gov/pubmed/20451243>

1140 Dong S, Sun J, Mao Z, Wang L, Lu YL *et al.* (2020). A guideline for homology modeling of the proteins  
1141 from newly discovered betacoronavirus, 2019 novel coronavirus (2019-nCoV). *J Med Virol*  
1142 <https://www.ncbi.nlm.nih.gov/pubmed/32181901>

1143 Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M *et al.* (2000). A novel angiotensin-  
1144 converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-  
1145 9. *Circ Res* **87**: E1-9 <https://www.ncbi.nlm.nih.gov/pubmed/10969042>

1146 Doyle S, Vaidya S, O'Connell R, Dadgostar H, Dempsey P *et al.* (2002). IRF3 mediates a TLR3/TLR4-  
1147 specific antiviral gene program. *Immunity* **17**: 251-63  
1148 <https://www.ncbi.nlm.nih.gov/pubmed/12354379>

1149 Eckerle LD, Becker MM, Halpin RA, Li K, Venter E *et al.* (2010). Infidelity of SARS-CoV Nsp14-  
1150 exonuclease mutant virus replication is revealed by complete genome sequencing. *PLoS*  
1151 *Pathog* **6**: e1000896 <https://www.ncbi.nlm.nih.gov/pubmed/20463816>

1152 Elfiky AA (2020). Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2  
1153 RNA dependent RNA polymerase (RdRp): A molecular docking study. *Life Sci* **117**: 592  
1154 <https://www.ncbi.nlm.nih.gov/pubmed/32222463>

1155 Esler M and Esler D (2020). Can angiotensin receptor-blocking drugs perhaps be harmful in the  
1156 COVID-19 pandemic? *J Hypertens* **38**: 781-782  
1157 <https://www.ncbi.nlm.nih.gov/pubmed/32195824>

1158 Ewart GD, Mills K, Cox GB and Gage PW (2002). Amiloride derivatives block ion channel activity and  
1159 enhancement of virus-like particle budding caused by HIV-1 protein Vpu. *Eur Biophys J* **31**:  
1160 26-35 <https://www.ncbi.nlm.nih.gov/pubmed/12046895>

1161 Ewart GD, Nasr N, Naif H, Cox GB, Cunningham AL *et al.* (2004). Potential new anti-human  
1162 immunodeficiency virus type 1 compounds depress virus replication in cultured human  
1163 macrophages. *Antimicrob Agents Chemother* **48**: 2325-30  
1164 <https://www.ncbi.nlm.nih.gov/pubmed/15155246>

1165 Fairweather SJ, Broer A, O'Mara ML and Broer S (2012). Intestinal peptidases form functional  
1166 complexes with the neutral amino acid transporter B(0)AT1. *Biochem J* **446**: 135-48  
1167 <https://www.ncbi.nlm.nih.gov/pubmed/22677001>

1168 Fan H, Ooi A, Tan YW, Wang S, Fang S *et al.* (2005). The nucleocapsid protein of coronavirus  
1169 infectious bronchitis virus: crystal structure of its N-terminal domain and multimerization  
1170 properties. *Structure* **13**: 1859-68 <https://www.ncbi.nlm.nih.gov/pubmed/16338414>

1171 Fehr AR and Perlman S (2015). Coronaviruses: an overview of their replication and pathogenesis.  
1172 *Methods Mol Biol* **1282**: 1-23 <https://www.ncbi.nlm.nih.gov/pubmed/25720466>

1173 Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB *et al.* (2005). Effect of angiotensin-  
 1174 converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-  
 1175 converting enzyme 2. *Circulation* **111**: 2605-10  
 1176 <https://www.ncbi.nlm.nih.gov/pubmed/15897343>  
 1177 Fitzgerald KA, McWhirter SM, Faia KL, Rowe DC, Latz E *et al.* (2003). IKK $\epsilon$  and TBK1 are essential  
 1178 components of the IRF3 signaling pathway. *Nat Immunol* **4**: 491-6  
 1179 <https://www.ncbi.nlm.nih.gov/pubmed/12692549>  
 1180 Fonseca BD, Zakaria C, Jia JJ, Graber TE, Svitkin Y *et al.* (2015). La-related Protein 1 (LARP1) Represses  
 1181 Terminal Oligopyrimidine (TOP) mRNA Translation Downstream of mTOR Complex 1  
 1182 (mTORC1). *J Biol Chem* **290**: 15996-6020 <https://www.ncbi.nlm.nih.gov/pubmed/25940091>  
 1183 Fung SY, Yuen KS, Ye ZW, Chan CP and Jin DY (2020). A tug-of-war between severe acute respiratory  
 1184 syndrome coronavirus 2 and host antiviral defence: lessons from other pathogenic viruses.  
 1185 *Emerg Microbes Infect* **9**: 558-570 <https://www.ncbi.nlm.nih.gov/pubmed/32172672>  
 1186 Gerl MJ, Sampaio JL, Urban S, Kalvodova L, Verbavatz JM *et al.* (2012). Quantitative analysis of the  
 1187 lipidomes of the influenza virus envelope and MDCK cell apical membrane. *J Cell Biol* **196**:  
 1188 213-21 <https://www.ncbi.nlm.nih.gov/pubmed/22249292>  
 1189 Glende J, Schwegmann-Wessels C, Al-Falah M, Pfefferle S, Qu X *et al.* (2008). Importance of  
 1190 cholesterol-rich membrane microdomains in the interaction of the S protein of SARS-  
 1191 coronavirus with the cellular receptor angiotensin-converting enzyme 2. *Virology* **381**: 215-  
 1192 21 <https://www.ncbi.nlm.nih.gov/pubmed/18814896>  
 1193 Goetz DH, Choe Y, Hansell E, Chen YT, McDowell M *et al.* (2007). Substrate specificity profiling and  
 1194 identification of a new class of inhibitor for the major protease of the SARS coronavirus.  
 1195 *Biochemistry* **46**: 8744-52 <https://www.ncbi.nlm.nih.gov/pubmed/17605471>  
 1196 Gordon CJ, Tchesnokov EP, Feng JY, Porter DP and Gotte M (2020a). The antiviral compound  
 1197 remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory  
 1198 syndrome coronavirus. *J Biol Chem* **295**: 4773-4779  
 1199 <https://www.ncbi.nlm.nih.gov/pubmed/32094225>  
 1200 Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K *et al.* (2020b). A SARS-CoV-2-Human Protein-  
 1201 Protein Interaction Map Reveals Drug Targets and Potential Drug Repurposing. *bioRxiv*  
 1202 <https://www.biorxiv.org/content/10.1101/2020.03.22.002386v3>  
 1203 <https://www.biorxiv.org/content/10.1101/2020.03.22.002386v3>  
 1204 Gotz C and Montenarh M (2017). Protein kinase CK2 in development and differentiation. *Biomed*  
 1205 *Rep* **6**: 127-133 <https://www.ncbi.nlm.nih.gov/pubmed/28357063>  
 1206 Goubau D, Deddouche S and Reis e Sousa C (2013). Cytosolic sensing of viruses. *Immunity* **38**: 855-69  
 1207 <https://www.ncbi.nlm.nih.gov/pubmed/23706667>  
 1208 Goubau D, Schlee M, Deddouche S, Pruijssers AJ, Zillinger T *et al.* (2014). Antiviral immunity via RIG-I-  
 1209 mediated recognition of RNA bearing 5'-diphosphates. *Nature* **514**: 372-375  
 1210 <https://www.ncbi.nlm.nih.gov/pubmed/25119032>  
 1211 Guo L, Fare CM and Shorter J (2019). Therapeutic Dissolution of Aberrant Phases by Nuclear-Import  
 1212 Receptors. *Trends Cell Biol* **29**: 308-322 <https://www.ncbi.nlm.nih.gov/pubmed/30660504>  
 1213 Hackbart M, Deng X and Baker SC (2020). Coronavirus endoribonuclease targets viral polyuridine  
 1214 sequences to evade activating host sensors. *Proc Natl Acad Sci U S A* **117**: 8094-8103  
 1215 <https://www.ncbi.nlm.nih.gov/pubmed/32198201>  
 1216 Haga S, Yamamoto N, Nakai-Murakami C, Osawa Y, Tokunaga K *et al.* (2008). Modulation of TNF- $\alpha$ -  
 1217 converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF- $\alpha$  production  
 1218 and facilitates viral entry. *Proc Natl Acad Sci U S A* **105**: 7809-14  
 1219 <https://www.ncbi.nlm.nih.gov/pubmed/18490652>



1220 Harcourt BH, Jukneliene D, Kanjanahaluethai A, Bechill J, Severson KM *et al.* (2004). Identification of  
 1221 severe acute respiratory syndrome coronavirus replicase products and characterization of  
 1222 papain-like protease activity. *J Virol* **78**: 13600-12  
 1223 <https://www.ncbi.nlm.nih.gov/pubmed/15564471>  
 1224 Hatesuer B, Bertram S, Mehnert N, Bahgat MM, Nelson PS *et al.* (2013). Tmprss2 is essential for  
 1225 influenza H1N1 virus pathogenesis in mice. *PLoS Pathog* **9**: e1003774  
 1226 <https://www.ncbi.nlm.nih.gov/pubmed/24348248>  
 1227 Heaton NS and Randall G (2011). Multifaceted roles for lipids in viral infection. *Trends Microbiol* **19**:  
 1228 368-75 <https://www.ncbi.nlm.nih.gov/pubmed/21530270>  
 1229 Herath CB, Warner FJ, Lubel JS, Dean RG, Jia Z *et al.* (2007). Upregulation of hepatic angiotensin-  
 1230 converting enzyme 2 (ACE2) and angiotensin-(1-7) levels in experimental biliary fibrosis. *J*  
 1231 *Hepatol* **47**: 387-95 <https://www.ncbi.nlm.nih.gov/pubmed/17532087>  
 1232 Hernandez Prada JA, Ferreira AJ, Katovich MJ, Shenoy V, Qi Y *et al.* (2008). Structure-based  
 1233 identification of small-molecule angiotensin-converting enzyme 2 activators as novel  
 1234 antihypertensive agents. *Hypertension* **51**: 1312-7  
 1235 <https://www.ncbi.nlm.nih.gov/pubmed/18391097>  
 1236 Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T *et al.* (2020). SARS-CoV-2 Cell Entry  
 1237 Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell*  
 1238 **181**: 271-280 e8 <https://www.ncbi.nlm.nih.gov/pubmed/32142651>  
 1239 Hogan PG, Chen L, Nardone J and Rao A (2003). Transcriptional regulation by calcium, calcineurin,  
 1240 and NFAT. *Genes Dev* **17**: 2205-32 <https://www.ncbi.nlm.nih.gov/pubmed/12975316>  
 1241 Holsinger LJ, Nichani D, Pinto LH and Lamb RA (1994). Influenza A virus M2 ion channel protein: a  
 1242 structure-function analysis. *J Virol* **68**: 1551-63  
 1243 <https://www.ncbi.nlm.nih.gov/pubmed/7508997>  
 1244 Hong S, Freeberg MA, Han T, Kamath A, Yao Y *et al.* (2017). LARP1 functions as a molecular switch  
 1245 for mTORC1-mediated translation of an essential class of mRNAs. *Elife* **6**:  
 1246 <https://www.ncbi.nlm.nih.gov/pubmed/28650797>  
 1247 Huang L, Sexton DJ, Skogerson K, Devlin M, Smith R *et al.* (2003). Novel peptide inhibitors of  
 1248 angiotensin-converting enzyme 2. *J Biol Chem* **278**: 15532-40  
 1249 <https://www.ncbi.nlm.nih.gov/pubmed/12606557>  
 1250 Imai Y, Kuba K, Rao S, Huan Y, Guo F *et al.* (2005). Angiotensin-converting enzyme 2 protects from  
 1251 severe acute lung failure. *Nature* **436**: 112-6  
 1252 <https://www.ncbi.nlm.nih.gov/pubmed/16001071>  
 1253 Inoue Y, Tanaka N, Tanaka Y, Inoue S, Morita K *et al.* (2007). Clathrin-dependent entry of severe  
 1254 acute respiratory syndrome coronavirus into target cells expressing ACE2 with the  
 1255 cytoplasmic tail deleted. *J Virol* **81**: 8722-9  
 1256 <https://www.ncbi.nlm.nih.gov/pubmed/17522231>  
 1257 Janeczko M, Orzeszko A, Kazimierczuk Z, Szyszka R and Baier A (2012). CK2 $\alpha$  and CK2 $\alpha'$  subunits  
 1258 differ in their sensitivity to 4,5,6,7-tetrabromo- and 4,5,6,7-tetraiodo-1H-benzimidazole  
 1259 derivatives. *Eur J Med Chem* **47**: 345-50 <https://www.ncbi.nlm.nih.gov/pubmed/22115617>  
 1260 Japp AG, Cruden NL, Barnes G, van Gemeren N, Mathews J *et al.* (2010). Acute cardiovascular effects  
 1261 of apelin in humans: potential role in patients with chronic heart failure. *Circulation* **121**:  
 1262 1818-27 <https://www.ncbi.nlm.nih.gov/pubmed/20385929>  
 1263 Jeon S, Ko M, Lee J, Choi I, Byun SY *et al.* (2020). Identification of antiviral drug candidates against  
 1264 SARS-CoV-2 from FDA-approved drugs. *bioRxiv*  
 1265 <https://www.biorxiv.org/content/10.1101/2020.03.20.999730v3>  
 1266 <https://www.biorxiv.org/content/10.1101/2020.03.20.999730v3>



1267 Jin Z, Du X, Xu Y, Deng Y, Liu M *et al.* (2020). Structure of M(pro) from COVID-19 virus and discovery  
1268 of its inhibitors. *Nature* <https://www.ncbi.nlm.nih.gov/pubmed/32272481>

1269 Kato H, Takeuchi O, Sato S, Yoneyama M, Yamamoto M *et al.* (2006). Differential roles of MDA5 and  
1270 RIG-I helicases in the recognition of RNA viruses. *Nature* **441**: 101-5  
1271 <https://www.ncbi.nlm.nih.gov/pubmed/16625202>

1272 Kawase M, Shirato K, van der Hoek L, Taguchi F and Matsuyama S (2012). Simultaneous treatment of  
1273 human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe  
1274 acute respiratory syndrome coronavirus entry. *J Virol* **86**: 6537-45  
1275 <https://www.ncbi.nlm.nih.gov/pubmed/22496216>

1276 Khan A, Benthin C, Zeno B, Albertson TE, Boyd J *et al.* (2017). A pilot clinical trial of recombinant  
1277 human angiotensin-converting enzyme 2 in acute respiratory distress syndrome. *Crit Care*  
1278 **21**: 234 <https://www.ncbi.nlm.nih.gov/pubmed/28877748>

1279 Kim SS, Sze L, Liu C and Lam KP (2019). The stress granule protein G3BP1 binds viral dsRNA and RIG-I  
1280 to enhance interferon- $\beta$  response. *J Biol Chem* **294**: 6430-6438  
1281 <https://www.ncbi.nlm.nih.gov/pubmed/30804210>

1282 Kim TS, Heinlein C, Hackman RC and Nelson PS (2006). Phenotypic analysis of mice lacking the  
1283 Tmprss2-encoded protease. *Mol Cell Biol* **26**: 965-75  
1284 <https://www.ncbi.nlm.nih.gov/pubmed/16428450>

1285 Kindler E, Thiel V and Weber F (2016). Interaction of SARS and MERS Coronaviruses with the Antiviral  
1286 Interferon Response. *Adv Virus Res* **96**: 219-243  
1287 <https://www.ncbi.nlm.nih.gov/pubmed/27712625>

1288 Knoops K, Kikkert M, Worm SH, Zevenhoven-Dobbe JC, van der Meer Y *et al.* (2008). SARS-  
1289 coronavirus replication is supported by a reticulovesicular network of modified endoplasmic  
1290 reticulum. *PLoS Biol* **6**: e226 <https://www.ncbi.nlm.nih.gov/pubmed/18798692>

1291 Kopecky-Bromberg SA, Martinez-Sobrido L, Frieman M, Baric RA and Palese P (2007). Severe acute  
1292 respiratory syndrome coronavirus open reading frame (ORF) 3b, ORF 6, and nucleocapsid  
1293 proteins function as interferon antagonists. *J Virol* **81**: 548-57  
1294 <https://www.ncbi.nlm.nih.gov/pubmed/17108024>

1295 Kosyna FK and Depping R (2018). Controlling the Gatekeeper: Therapeutic Targeting of Nuclear  
1296 Transport. *Cells* **7**: <https://www.ncbi.nlm.nih.gov/pubmed/30469340>

1297 Kowalczyk S, Broer A, Tietze N, Vanslambrouck JM, Rasko JE *et al.* (2008). A protein complex in the  
1298 brush-border membrane explains a Hartnup disorder allele. *FASEB J* **22**: 2880-7  
1299 <https://www.ncbi.nlm.nih.gov/pubmed/18424768>

1300 Krzystyniak K and Dupuy JM (1984). Entry of mouse hepatitis virus 3 into cells. *J Gen Virol* **65 ( Pt 1)**:  
1301 227-31 <https://www.ncbi.nlm.nih.gov/pubmed/6319570>

1302 Kuba K, Imai Y, Rao S, Gao H, Guo F *et al.* (2005). A crucial role of angiotensin converting enzyme 2  
1303 (ACE2) in SARS coronavirus-induced lung injury. *Nat Med* **11**: 875-9  
1304 <https://www.ncbi.nlm.nih.gov/pubmed/16007097>

1305 Kuba K, Imai Y, Ohto-Nakanishi T and Penninger JM (2010). Trilogy of ACE2: a peptidase in the renin-  
1306 angiotensin system, a SARS receptor, and a partner for amino acid transporters. *Pharmacol*  
1307 *Ther* **128**: 119-28 <https://www.ncbi.nlm.nih.gov/pubmed/20599443>

1308 Kulemina LV and Ostrov DA (2011). Prediction of off-target effects on angiotensin-converting  
1309 enzyme 2. *J Biomol Screen* **16**: 878-85 <https://www.ncbi.nlm.nih.gov/pubmed/21859683>

1310 Lambert DW, Yarski M, Warner FJ, Thornhill P, Parkin ET *et al.* (2005). Tumor necrosis factor- $\alpha$   
1311 convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute  
1312 respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2  
1313 (ACE2). *J Biol Chem* **280**: 30113-9 <https://www.ncbi.nlm.nih.gov/pubmed/15983030>

1314 Lang J, Yang N, Deng J, Liu K, Yang P *et al.* (2011). Inhibition of SARS pseudovirus cell entry by  
 1315 lactoferrin binding to heparan sulfate proteoglycans. *PLoS One* **6**: e23710  
 1316 <https://www.ncbi.nlm.nih.gov/pubmed/21887302>  
 1317 Lei C, Qian K, Li T, Zhang S, Fu W *et al.* (2020). Neutralization of SARS-CoV-2 spike pseudotyped virus  
 1318 by recombinant ACE2-Ig. *Nat Commun* **11**: 2070  
 1319 <https://www.ncbi.nlm.nih.gov/pubmed/32332765>  
 1320 <https://www.nature.com/articles/s41467-020-16048-4.pdf>  
 1321 Lei J, Kusov Y and Hilgenfeld R (2018). Nsp3 of coronaviruses: Structures and functions of a large  
 1322 multi-domain protein. *Antiviral Res* **149**: 58-74  
 1323 <https://www.ncbi.nlm.nih.gov/pubmed/29128390>  
 1324 Lemmon MA (2008). Membrane recognition by phospholipid-binding domains. *Nat Rev Mol Cell Biol*  
 1325 **9**: 99-111 <https://www.ncbi.nlm.nih.gov/pubmed/18216767>  
 1326 Letko M, Marzi A and Munster V (2020). Functional assessment of cell entry and receptor usage for  
 1327 SARS-CoV-2 and other lineage B betacoronaviruses. *Nat Microbiol* **5**: 562-569  
 1328 <https://www.ncbi.nlm.nih.gov/pubmed/32094589>  
 1329 Lew RA, Warner FJ, Hanchapola I, Yarski MA, Ramchand J *et al.* (2008). Angiotensin-converting  
 1330 enzyme 2 catalytic activity in human plasma is masked by an endogenous inhibitor. *Exp*  
 1331 *Physiol* **93**: 685-93 <https://www.ncbi.nlm.nih.gov/pubmed/18223027>  
 1332 Li B, Yang J, Zhao F, Zhi L, Wang X *et al.* (2020a). Prevalence and impact of cardiovascular metabolic  
 1333 diseases on COVID-19 in China. *Clin Res Cardiol*  
 1334 <https://www.ncbi.nlm.nih.gov/pubmed/32161990>  
 1335 Li F, Li W, Farzan M and Harrison SC (2005). Structure of SARS coronavirus spike receptor-binding  
 1336 domain complexed with receptor. *Science* **309**: 1864-8  
 1337 <https://www.ncbi.nlm.nih.gov/pubmed/16166518>  
 1338 Li G and De Clercq E (2020). Therapeutic options for the 2019 novel coronavirus (2019-nCoV). *Nat*  
 1339 *Rev Drug Discov* **19**: 149-150 <https://www.ncbi.nlm.nih.gov/pubmed/32127666>  
 1340 Li R, Qiao S and Zhang G (2020b). Analysis of angiotensin-converting enzyme 2 (ACE2) from different  
 1341 species sheds some light on cross-species receptor usage of a novel coronavirus 2019-nCoV.  
 1342 *J Infect* **80**: 469-496 <https://www.ncbi.nlm.nih.gov/pubmed/32092392>  
 1343 Li TC, Chan MC and Lee N (2015). Clinical Implications of Antiviral Resistance in Influenza. *Viruses* **7**:  
 1344 4929-44 <https://www.ncbi.nlm.nih.gov/pubmed/26389935>  
 1345 Li W, Moore MJ, Vasilieva N, Sui J, Wong SK *et al.* (2003). Angiotensin-converting enzyme 2 is a  
 1346 functional receptor for the SARS coronavirus. *Nature* **426**: 450-4  
 1347 <https://www.ncbi.nlm.nih.gov/pubmed/14647384>  
 1348 Lin B, Ferguson C, White JT, Wang S, Vessella R *et al.* (1999). Prostate-localized and androgen-  
 1349 regulated expression of the membrane-bound serine protease *TMPRSS2*. *Cancer Res* **59**:  
 1350 4180-4 <https://www.ncbi.nlm.nih.gov/pubmed/10485450>  
 1351 Lindner HA, Fotouhi-Ardakani N, Lytvyn V, Lachance P, Sulea T *et al.* (2005). The papain-like protease  
 1352 from the severe acute respiratory syndrome coronavirus is a deubiquitinating enzyme. *J*  
 1353 *Virol* **79**: 15199-208 <https://www.ncbi.nlm.nih.gov/pubmed/16306591>  
 1354 Lindner HA, Lytvyn V, Qi H, Lachance P, Ziomek E *et al.* (2007). Selectivity in ISG15 and ubiquitin  
 1355 recognition by the SARS coronavirus papain-like protease. *Arch Biochem Biophys* **466**: 8-14  
 1356 <https://www.ncbi.nlm.nih.gov/pubmed/17692280>  
 1357 Lippi G, Lavie CJ and Sanchis-Gomar F (2020). Cardiac troponin I in patients with coronavirus disease  
 1358 2019 (COVID-19): Evidence from a meta-analysis. *Prog Cardiovasc Dis*  
 1359 <https://www.ncbi.nlm.nih.gov/pubmed/32169400>

1360 Liu XY, Wei B, Shi HX, Shan YF and Wang C (2010). Tom70 mediates activation of interferon  
 1361 regulatory factor 3 on mitochondria. *Cell Res* **20**: 994-1011  
 1362 <https://www.ncbi.nlm.nih.gov/pubmed/20628368>  
 1363 Liu ZS, Cai H, Xue W, Wang M, Xia T *et al.* (2019). G3BP1 promotes DNA binding and activation of  
 1364 cGAS. *Nat Immunol* **20**: 18-28 <https://www.ncbi.nlm.nih.gov/pubmed/30510222>  
 1365 Lopez LA, Riffle AJ, Pike SL, Gardner D and Hogue BG (2008). Importance of conserved cysteine  
 1366 residues in the coronavirus envelope protein. *J Virol* **82**: 3000-10  
 1367 <https://www.ncbi.nlm.nih.gov/pubmed/18184703>  
 1368 Lu G, Wang Q and Gao GF (2015). Bat-to-human: spike features determining 'host jump' of  
 1369 coronaviruses SARS-CoV, MERS-CoV, and beyond. *Trends Microbiol* **23**: 468-78  
 1370 <https://www.ncbi.nlm.nih.gov/pubmed/26206723>  
 1371 Lu R, Zhao X, Li J, Niu P, Yang B *et al.* (2020). Genomic characterisation and epidemiology of 2019  
 1372 novel coronavirus: implications for virus origins and receptor binding. *Lancet* **395**: 565-574  
 1373 <https://www.ncbi.nlm.nih.gov/pubmed/32007145>  
 1374 Lu W, Zheng BJ, Xu K, Schwarz W, Du L *et al.* (2006). Severe acute respiratory syndrome-associated  
 1375 coronavirus 3a protein forms an ion channel and modulates virus release. *Proc Natl Acad Sci*  
 1376 *U S A* **103**: 12540-5 <https://www.ncbi.nlm.nih.gov/pubmed/16894145>  
 1377 Luan J, Lu Y, Jin X and Zhang L (2020). Spike protein recognition of mammalian ACE2 predicts the  
 1378 host range and an optimized ACE2 for SARS-CoV-2 infection. *Biochem Biophys Res Commun*  
 1379 <https://www.ncbi.nlm.nih.gov/pubmed/32201080>  
 1380 Lucas JM, True L, Hawley S, Matsumura M, Morrissey C *et al.* (2008). The androgen-regulated type II  
 1381 serine protease TMPRSS2 is differentially expressed and mislocalized in prostate  
 1382 adenocarcinoma. *J Pathol* **215**: 118-25 <https://www.ncbi.nlm.nih.gov/pubmed/18338334>  
 1383 Lucas JM, Heinlein C, Kim T, Hernandez SA, Malik MS *et al.* (2014). The androgen-regulated protease  
 1384 TMPRSS2 activates a proteolytic cascade involving components of the tumor  
 1385 microenvironment and promotes prostate cancer metastasis. *Cancer Discov* **4**: 1310-25  
 1386 <https://www.ncbi.nlm.nih.gov/pubmed/25122198>  
 1387 Lukassen S, Chua RL, Trefzer T, Kahn NC, Schneider MA *et al.* (2020). SARS-CoV-2 receptor ACE2 and  
 1388 TMPRSS2 are primarily expressed in bronchial transient secretory cells. *EMBO J* e105114  
 1389 <https://www.ncbi.nlm.nih.gov/pubmed/32246845>  
 1390 Mangan MSJ, Olhava EJ, Roush WR, Seidel HM, Glick GD *et al.* (2018). Targeting the NLRP3  
 1391 inflammasome in inflammatory diseases. *Nat Rev Drug Discov* **17**: 688  
 1392 <https://www.ncbi.nlm.nih.gov/pubmed/30116046>  
 1393 Masters PS (2006). The molecular biology of coronaviruses. *Adv Virus Res* **66**: 193-292  
 1394 <https://www.ncbi.nlm.nih.gov/pubmed/16877062>  
 1395 Matsuyama S, Nao N, Shirato K, Kawase M, Saito S *et al.* (2020). Enhanced isolation of SARS-CoV-2 by  
 1396 TMPRSS2-expressing cells. *Proc Natl Acad Sci U S A* **117**: 7001-7003  
 1397 <https://www.ncbi.nlm.nih.gov/pubmed/32165541>  
 1398 Mazzon M and Mercer J (2014). Lipid interactions during virus entry and infection. *Cell Microbiol* **16**:  
 1399 1493-502 <https://www.ncbi.nlm.nih.gov/pubmed/25131438>  
 1400 McBride R, van Zyl M and Fielding BC (2014). The coronavirus nucleocapsid is a multifunctional  
 1401 protein. *Viruses* **6**: 2991-3018 <https://www.ncbi.nlm.nih.gov/pubmed/25105276>  
 1402 Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS *et al.* (2020). COVID-19: consider cytokine  
 1403 storm syndromes and immunosuppression. *Lancet* **395**: 1033-1034  
 1404 <https://www.ncbi.nlm.nih.gov/pubmed/32192578>  
 1405 Mesel-Lemoine M, Millet J, Vidalain PO, Law H, Vabret A *et al.* (2012). A human coronavirus  
 1406 responsible for the common cold massively kills dendritic cells but not monocytes. *J Virol* **86**:  
 1407 7577-87 <https://www.ncbi.nlm.nih.gov/pubmed/22553325>

1408 Meyer D, Sielaff F, Hammami M, Bottcher-Friebertshauser E, Garten W *et al.* (2013). Identification of  
1409 the first synthetic inhibitors of the type II transmembrane serine protease TMPRSS2 suitable  
1410 for inhibition of influenza virus activation. *Biochem J* **452**: 331-43  
1411 <https://www.ncbi.nlm.nih.gov/pubmed/23527573>

1412 Millet JK and Whittaker GR (2015). Host cell proteases: Critical determinants of coronavirus tropism  
1413 and pathogenesis. *Virus Res* **202**: 120-34 <https://www.ncbi.nlm.nih.gov/pubmed/25445340>

1414 Minakshi R, Padhan K, Rehman S, Hassan MI and Ahmad F (2014). The SARS Coronavirus 3a protein  
1415 binds calcium in its cytoplasmic domain. *Virus Res* **191**: 180-3  
1416 <https://www.ncbi.nlm.nih.gov/pubmed/25116391>

1417 Minato T, Nirasawa S, Sato T, Yamaguchi T, Hoshizaki M *et al.* (2020). B38-CAP is a bacteria-derived  
1418 ACE2-like enzyme that suppresses hypertension and cardiac dysfunction. *Nat Commun* **11**:  
1419 1058 <https://www.ncbi.nlm.nih.gov/pubmed/32103002>

1420 Mizzen L, Hilton A, Cheley S and Anderson R (1985). Attenuation of murine coronavirus infection by  
1421 ammonium chloride. *Virology* **142**: 378-88 <https://www.ncbi.nlm.nih.gov/pubmed/2997991>

1422 Mores A, Matziari M, Beau F, Cuniasse P, Yiotakis A *et al.* (2008). Development of potent and  
1423 selective phosphinic peptide inhibitors of angiotensin-converting enzyme 2. *J Med Chem* **51**:  
1424 2216-26 <https://www.ncbi.nlm.nih.gov/pubmed/18324760>

1425 Muller C, Hardt M, Schwudke D, Neuman BW, Pleschka S *et al.* (2018). Inhibition of Cytosolic  
1426 Phospholipase A2alpha Impairs an Early Step of Coronavirus Replication in Cell Culture. *J*  
1427 *Virol* **92**: <https://www.ncbi.nlm.nih.gov/pubmed/29167338>

1428 Mycroft-West C, Su D, Elli S, Guimond S, Miller G *et al.* (2020). The 2019 coronavirus (SARS-CoV-2)  
1429 surface protein (Spike) S1 Receptor Binding Domain undergoes conformational change upon  
1430 heparin binding. *bioRxiv* <https://www.biorxiv.org/content/10.1101/2020.02.29.971093v1>  
1431 <https://www.biorxiv.org/content/10.1101/2020.02.29.971093v1>

1432 Najjar M, Suebsuwong C, Ray SS, Thapa RJ, Maki JL *et al.* (2015). Structure guided design of potent  
1433 and selective ponatinib-based hybrid inhibitors for RIPK1. *Cell Rep* **10**: 1850-60  
1434 <https://www.ncbi.nlm.nih.gov/pubmed/25801024>

1435 Nakagawa K, Narayanan K, Wada M, Popov VL, Cajimat M *et al.* (2018). The Endonucleolytic RNA  
1436 Cleavage Function of nsp1 of Middle East Respiratory Syndrome Coronavirus Promotes the  
1437 Production of Infectious Virus Particles in Specific Human Cell Lines. *J Virol* **92**:  
1438 <https://www.ncbi.nlm.nih.gov/pubmed/30111568>

1439 Nelson PH, Eugui E, Wang CC and Allison AC (1990). Synthesis and immunosuppressive activity of  
1440 some side-chain variants of mycophenolic acid. *J Med Chem* **33**: 833-8  
1441 <https://www.ncbi.nlm.nih.gov/pubmed/1967654>

1442 Nieto-Torres JL, DeDiego ML, Verdia-Baguena C, Jimenez-Guardeno JM, Regla-Nava JA *et al.* (2014).  
1443 Severe acute respiratory syndrome coronavirus envelope protein ion channel activity  
1444 promotes virus fitness and pathogenesis. *PLoS Pathog* **10**: e1004077  
1445 <https://www.ncbi.nlm.nih.gov/pubmed/24788150>

1446 Nieto-Torres JL, Verdia-Baguena C, Jimenez-Guardeno JM, Regla-Nava JA, Castano-Rodriguez C *et al.*  
1447 (2015). Severe acute respiratory syndrome coronavirus E protein transports calcium ions and  
1448 activates the NLRP3 inflammasome. *Virology* **485**: 330-9  
1449 <https://www.ncbi.nlm.nih.gov/pubmed/26331680>

1450 Ocaranza MP, Godoy I, Jalil JE, Varas M, Collantes P *et al.* (2006). Enalapril attenuates  
1451 downregulation of Angiotensin-converting enzyme 2 in the late phase of ventricular  
1452 dysfunction in myocardial infarcted rat. *Hypertension* **48**: 572-8  
1453 <https://www.ncbi.nlm.nih.gov/pubmed/16908757>

1454 Olds JL and Kabbani N (2020). Is nicotine exposure linked to cardiopulmonary vulnerability to COVID-  
1455 19 in the general population? *FEBS J* <https://www.ncbi.nlm.nih.gov/pubmed/32189428>



1456 Oostra M, de Haan CA and Rottier PJ (2007). The 29-nucleotide deletion present in human but not in  
 1457 animal severe acute respiratory syndrome coronaviruses disrupts the functional expression  
 1458 of open reading frame 8. *J Virol* **81**: 13876-88  
 1459 <https://www.ncbi.nlm.nih.gov/pubmed/17928347>  
 1460 Organization WH (2020). WHO Technical Guidance. *Journal*  
 1461 [https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it)  
 1462 [guidance/naming-the-coronavirus-disease-\(covid-2019\)-and-the-virus-that-causes-it](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it)  
 1463 Oudit GY, Liu GC, Zhong J, Basu R, Chow FL *et al.* (2010). Human recombinant ACE2 reduces the  
 1464 progression of diabetic nephropathy. *Diabetes* **59**: 529-38  
 1465 <https://www.ncbi.nlm.nih.gov/pubmed/19934006>  
 1466 Paoloni-Giacobino A, Chen H, Peitsch MC, Rossier C and Antonarakis SE (1997). Cloning of the  
 1467 TMPRSS2 gene, which encodes a novel serine protease with transmembrane, LDLRA, and  
 1468 SRCR domains and maps to 21q22.3. *Genomics* **44**: 309-20  
 1469 <https://www.ncbi.nlm.nih.gov/pubmed/9325052>  
 1470 Paszti-Gere E, Czimmermann E, Ujhelyi G, Balla P, Maiwald A *et al.* (2016). In vitro characterization of  
 1471 TMPRSS2 inhibition in IPEC-J2 cells. *J Enzyme Inhib Med Chem* **31**: 123-129  
 1472 <https://www.ncbi.nlm.nih.gov/pubmed/27277342>  
 1473 Pervushin K, Tan E, Parthasarathy K, Lin X, Jiang FL *et al.* (2009). Structure and inhibition of the SARS  
 1474 coronavirus envelope protein ion channel. *PLoS Pathog* **5**: e1000511  
 1475 <https://www.ncbi.nlm.nih.gov/pubmed/19593379>  
 1476 Petit CM, Melancon JM, Chouljenko VN, Colgrove R, Farzan M *et al.* (2005). Genetic analysis of the  
 1477 SARS-coronavirus spike glycoprotein functional domains involved in cell-surface expression  
 1478 and cell-to-cell fusion. *Virology* **341**: 215-30  
 1479 <https://www.ncbi.nlm.nih.gov/pubmed/16099010>  
 1480 Petit CM, Chouljenko VN, Iyer A, Colgrove R, Farzan M *et al.* (2007). Palmitoylation of the cysteine-  
 1481 rich endodomain of the SARS-coronavirus spike glycoprotein is important for spike-mediated  
 1482 cell fusion. *Virology* **360**: 264-74 <https://www.ncbi.nlm.nih.gov/pubmed/17134730>  
 1483 Pfefferle S, Schopf J, Kogl M, Friedel CC, Muller MA *et al.* (2011). The SARS-coronavirus-host  
 1484 interactome: identification of cyclophilins as target for pan-coronavirus inhibitors. *PLoS*  
 1485 *Pathog* **7**: e1002331 <https://www.ncbi.nlm.nih.gov/pubmed/22046132>  
 1486 Philippe L, van den Elzen AMG, Watson MJ and Thoreen CC (2020). Global analysis of LARP1  
 1487 translation targets reveals tunable and dynamic features of 5' TOP motifs. *Proc Natl Acad Sci*  
 1488 *U S A* **117**: 5319-5328 <https://www.ncbi.nlm.nih.gov/pubmed/32094190>  
 1489 Pierre F, Chua PC, O'Brien SE, Siddiqui-Jain A, Bourbon P *et al.* (2011). Discovery and SAR of 5-(3-  
 1490 chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid (CX-4945), the first clinical  
 1491 stage inhibitor of protein kinase CK2 for the treatment of cancer. *J Med Chem* **54**: 635-54  
 1492 <https://www.ncbi.nlm.nih.gov/pubmed/21174434>  
 1493 Pillaiyar T, Meenakshisundaram S and Manickam M (2020). Recent discovery and development of  
 1494 inhibitors targeting coronaviruses. *Drug Discov Today*  
 1495 <https://www.ncbi.nlm.nih.gov/pubmed/32006468>  
 1496 Pinto LH, Holsinger LJ and Lamb RA (1992). Influenza virus M<sub>2</sub> protein has ion channel activity. *Cell*  
 1497 **69**: 517-28 <https://www.ncbi.nlm.nih.gov/pubmed/1374685>  
 1498 Putics A, Filipowicz W, Hall J, Gorbalenya AE and Ziebuhr J (2005). ADP-ribose-1"-monophosphatase:  
 1499 a conserved coronavirus enzyme that is dispensable for viral replication in tissue culture. *J*  
 1500 *Virol* **79**: 12721-31 <https://www.ncbi.nlm.nih.gov/pubmed/16188975>  
 1501 Raj VS, Mou H, Smits SL, Dekkers DH, Muller MA *et al.* (2013). Dipeptidyl peptidase 4 is a functional  
 1502 receptor for the emerging human coronavirus-EMC. *Nature* **495**: 251-4  
 1503 <https://www.ncbi.nlm.nih.gov/pubmed/23486063>



1504 Ratia K, Saikatendu KS, Santarsiero BD, Barretto N, Baker SC *et al.* (2006). Severe acute respiratory  
 1505 syndrome coronavirus papain-like protease: structure of a viral deubiquitinating enzyme.  
 1506 *Proc Natl Acad Sci U S A* **103**: 5717-22 <https://www.ncbi.nlm.nih.gov/pubmed/16581910>  
 1507 Ratia K, Kilianski A, Baez-Santos YM, Baker SC and Mesecar A (2014). Structural Basis for the  
 1508 Ubiquitin-Linkage Specificity and deISGylating activity of SARS-CoV papain-like protease.  
 1509 *PLoS Pathog* **10**: e1004113 <https://www.ncbi.nlm.nih.gov/pubmed/24854014>  
 1510 Roberts A, Vogel L, Guarner J, Hayes N, Murphy B *et al.* (2005). Severe acute respiratory syndrome  
 1511 coronavirus infection of golden Syrian hamsters. *J Virol* **79**: 503-11  
 1512 <https://www.ncbi.nlm.nih.gov/pubmed/15596843>  
 1513 Roberts A, Thomas WD, Guarner J, Lamirande EW, Babcock GJ *et al.* (2006). Therapy with a severe  
 1514 acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal  
 1515 antibody reduces disease severity and viral burden in golden Syrian hamsters. *J Infect Dis*  
 1516 **193**: 685-92 <https://www.ncbi.nlm.nih.gov/pubmed/16453264>  
 1517 Ruch TR and Machamer CE (2012). The coronavirus E protein: assembly and beyond. *Viruses* **4**: 363-  
 1518 82 <https://www.ncbi.nlm.nih.gov/pubmed/22590676>  
 1519 Schafer B, Marg B, Gschwind A and Ullrich A (2004). Distinct ADAM metalloproteinases regulate G  
 1520 protein-coupled receptor-induced cell proliferation and survival. *J Biol Chem* **279**: 47929-38  
 1521 <https://www.ncbi.nlm.nih.gov/pubmed/15337756>  
 1522 <https://www.jbc.org/content/279/46/47929.full.pdf>  
 1523 Schlee M (2013). Master sensors of pathogenic RNA - RIG-I like receptors. *Immunobiology* **218**: 1322-  
 1524 35 <https://www.ncbi.nlm.nih.gov/pubmed/23896194>  
 1525 Sevajol M, Subissi L, Decroly E, Canard B and Imbert I (2014). Insights into RNA synthesis, capping,  
 1526 and proofreading mechanisms of SARS-coronavirus. *Virus Res* **194**: 90-9  
 1527 <https://www.ncbi.nlm.nih.gov/pubmed/25451065>  
 1528 Sharma S, tenOever BR, Grandvaux N, Zhou GP, Lin R *et al.* (2003). Triggering the interferon antiviral  
 1529 response through an IKK-related pathway. *Science* **300**: 1148-51  
 1530 <https://www.ncbi.nlm.nih.gov/pubmed/12702806>  
 1531 Shi CS, Qi HY, Boularan C, Huang NN, Abu-Asab M *et al.* (2014). SARS-coronavirus open reading  
 1532 frame-9b suppresses innate immunity by targeting mitochondria and the  
 1533 MAVS/TRAF3/TRAF6 signalosome. *J Immunol* **193**: 3080-9  
 1534 <https://www.ncbi.nlm.nih.gov/pubmed/25135833>  
 1535 Shi J, Wen Z, Zhong G, Yang H, Wang C *et al.* (2020a). Susceptibility of ferrets, cats, dogs, and other  
 1536 domesticated animals to SARS-coronavirus 2. *Science*  
 1537 <https://www.ncbi.nlm.nih.gov/pubmed/32269068>  
 1538 Shi J, Wen Z, Zhong G, Yang H, Wang C *et al.* (2020b). Susceptibility of ferrets, cats, dogs, and  
 1539 different domestic animals to SARS-coronavirus-2. *bioRxiv*  
 1540 <https://www.biorxiv.org/content/10.1101/2020.03.30.015347v1>  
 1541 <https://www.biorxiv.org/content/10.1101/2020.03.30.015347v1>  
 1542 Shi Y, Wang Y, Shao C, Huang J, Gan J *et al.* (2020c). COVID-19 infection: the perspectives on immune  
 1543 responses. *Cell Death Differ* <https://www.ncbi.nlm.nih.gov/pubmed/32205856>  
 1544 Simmons G, Gosalia DN, Rennekamp AJ, Reeves JD, Diamond SL *et al.* (2005). Inhibitors of cathepsin  
 1545 L prevent severe acute respiratory syndrome coronavirus entry. *Proc Natl Acad Sci U S A*  
 1546 **102**: 11876-81 <https://www.ncbi.nlm.nih.gov/pubmed/16081529>  
 1547 Sims AC, Tilton SC, Menachery VD, Gralinski LE, Schafer A *et al.* (2013). Release of severe acute  
 1548 respiratory syndrome coronavirus nuclear import block enhances host transcription in  
 1549 human lung cells. *J Virol* **87**: 3885-902 <https://www.ncbi.nlm.nih.gov/pubmed/23365422>  
 1550 Siu KL, Yuen KS, Castano-Rodriguez C, Ye ZW, Yeung ML *et al.* (2019). Severe acute respiratory  
 1551 syndrome coronavirus ORF3a protein activates the NLRP3 inflammasome by promoting

1552 TRAF3-dependent ubiquitination of ASC. *FASEB J* **33**: 8865-8877  
 1553 <https://www.ncbi.nlm.nih.gov/pubmed/31034780>

1554 Snijder EJ, Bredenbeek PJ, Dobbe JC, Thiel V, Ziebuhr J *et al.* (2003). Unique and conserved features  
 1555 of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group  
 1556 2 lineage. *J Mol Biol* **331**: 991-1004 <https://www.ncbi.nlm.nih.gov/pubmed/12927536>

1557 Song Z, Xu Y, Bao L, Zhang L, Yu P *et al.* (2019). From SARS to MERS, Thrusting Coronaviruses into the  
 1558 Spotlight. *Viruses* **11**: <https://www.ncbi.nlm.nih.gov/pubmed/30646565>

1559 Srinivasan S, Cui H, Gao Z, Liu M, Lu S *et al.* (2020). Structural Genomics of SARS-CoV-2 Indicates  
 1560 Evolutionary Conserved Functional Regions of Viral Proteins. *Viruses* **12**:  
 1561 <https://www.ncbi.nlm.nih.gov/pubmed/32218151>

1562 Sriramula S, Pedersen KB, Xia H and Lazartigues E (2017). Determining the Enzymatic Activity of  
 1563 Angiotensin-Converting Enzyme 2 (ACE2) in Brain Tissue and Cerebrospinal Fluid Using a  
 1564 Quenched Fluorescent Substrate. *Methods Mol Biol* **1527**: 117-126  
 1565 <https://www.ncbi.nlm.nih.gov/pubmed/28116711>

1566 Surya W, Li Y, Verdia-Baguena C, Aguilera VM and Torres J (2015). MERS coronavirus envelope  
 1567 protein has a single transmembrane domain that forms pentameric ion channels. *Virus Res*  
 1568 **201**: 61-6 <https://www.ncbi.nlm.nih.gov/pubmed/25733052>

1569 Swarthout JT, Lobo S, Farh L, Croke MR, Greentree WK *et al.* (2005). DHHC9 and GCP16 constitute a  
 1570 human protein fatty acyltransferase with specificity for H- and N-Ras. *J Biol Chem* **280**:  
 1571 31141-8 <https://www.ncbi.nlm.nih.gov/pubmed/16000296>

1572 Tanabe LM and List K (2017). The role of type II transmembrane serine protease-mediated signaling  
 1573 in cancer. *FEBS J* **284**: 1421-1436 <https://www.ncbi.nlm.nih.gov/pubmed/27870503>

1574 Tarnow C, Engels G, Arendt A, Schwalm F, Sediri H *et al.* (2014). TMPRSS2 is a host factor that is  
 1575 essential for pneumotropism and pathogenicity of H7N9 influenza A virus in mice. *J Virol* **88**:  
 1576 4744-51 <https://www.ncbi.nlm.nih.gov/pubmed/24522916>

1577 Thiel V, Ivanov KA, Putics A, Hertzog T, Schelle B *et al.* (2003). Mechanisms and enzymes involved in  
 1578 SARS coronavirus genome expression. *J Gen Virol* **84**: 2305-2315  
 1579 <https://www.ncbi.nlm.nih.gov/pubmed/12917450>

1580 Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G *et al.* (2000). A human homolog of angiotensin-  
 1581 converting enzyme. Cloning and functional expression as a captopril-insensitive  
 1582 carboxypeptidase. *J Biol Chem* **275**: 33238-43  
 1583 <https://www.ncbi.nlm.nih.gov/pubmed/10924499>

1584 Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R *et al.* (2005). Recurrent fusion of  
 1585 TMPRSS2 and ETS transcription factor genes in prostate cancer. *Science* **310**: 644-8  
 1586 <https://www.ncbi.nlm.nih.gov/pubmed/16254181>

1587 Torres J, Maheswari U, Parthasarathy K, Ng L, Liu DX *et al.* (2007). Conductance and amantadine  
 1588 binding of a pore formed by a lysine-flanked transmembrane domain of SARS coronavirus  
 1589 envelope protein. *Protein Sci* **16**: 2065-71 <https://www.ncbi.nlm.nih.gov/pubmed/17766393>

1590 Uhlen M, Fagerberg L, Hallstrom BM, Lindskog C, Oksvold P *et al.* (2015). Proteomics. Tissue-based  
 1591 map of the human proteome. *Science* **347**: 1260419  
 1592 <https://www.ncbi.nlm.nih.gov/pubmed/25613900>

1593 Vanle B, Olcott W, Jimenez J, Bashmi L, Danovitch I *et al.* (2018). NMDA antagonists for treating the  
 1594 non-motor symptoms in Parkinson's disease. *Transl Psychiatry* **8**: 117  
 1595 <https://www.ncbi.nlm.nih.gov/pubmed/29907742>

1596 Vardavas CI and Nikitara K (2020). COVID-19 and smoking: A systematic review of the evidence. *Tob*  
 1597 *Induc Dis* **18**: 20 <https://www.ncbi.nlm.nih.gov/pubmed/32206052>

1598 Vickers C, Hales P, Kaushik V, Dick L, Gavin J *et al.* (2002). Hydrolysis of biological peptides by human  
1599 angiotensin-converting enzyme-related carboxypeptidase. *J Biol Chem* **277**: 14838-43  
1600 <https://www.ncbi.nlm.nih.gov/pubmed/11815627>

1601 Viruses CSGotlCoTo (2020). The species Severe acute respiratory syndrome-related coronavirus:  
1602 classifying 2019-nCoV and naming it SARS-CoV-2. *Nat Microbiol* **5**: 536-544  
1603 <https://www.ncbi.nlm.nih.gov/pubmed/32123347>

1604 Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT *et al.* (2020). Structure, Function, and  
1605 Antigenicity of the SARS-CoV-2 Spike Glycoprotein. *Cell* **181**: 281-292 e6  
1606 <https://www.ncbi.nlm.nih.gov/pubmed/32155444>

1607 Wang C, Takeuchi K, Pinto LH and Lamb RA (1993). Ion channel activity of influenza A virus M2  
1608 protein: characterization of the amantadine block. *J Virol* **67**: 5585-94  
1609 <https://www.ncbi.nlm.nih.gov/pubmed/7688826>

1610 Wang C, Chen T, Zhang J, Yang M, Li N *et al.* (2009). The E3 ubiquitin ligase Nrdp1 'preferentially'  
1611 promotes TLR-mediated production of type I interferon. *Nat Immunol* **10**: 744-52  
1612 <https://www.ncbi.nlm.nih.gov/pubmed/19483718>

1613 Wilson L, McKinlay C, Gage P and Ewart G (2004). SARS coronavirus E protein forms cation-selective  
1614 ion channels. *Virology* **330**: 322-31 <https://www.ncbi.nlm.nih.gov/pubmed/15527857>

1615 Wilson S, Greer B, Hooper J, Zijlstra A, Walker B *et al.* (2005). The membrane-anchored serine  
1616 protease, TMPRSS2, activates PAR-2 in prostate cancer cells. *Biochem J* **388**: 967-72  
1617 <https://www.ncbi.nlm.nih.gov/pubmed/15537383>

1618 Wisner C, Kim B and Ascano M (2019). G3BP1 enhances cytoplasmic DNA pattern recognition. *Nat*  
1619 *Immunol* **20**: 5-7 <https://www.ncbi.nlm.nih.gov/pubmed/30538338>

1620 Wittine K, Stipkovic Babic M, Makuc D, Plavec J, Kraljevic Pavelic S *et al.* (2012). Novel 1,2,4-triazole  
1621 and imidazole derivatives of L-ascorbic and imino-ascorbic acid: synthesis, anti-HCV and  
1622 antitumor activity evaluations. *Bioorg Med Chem* **20**: 3675-85  
1623 <https://www.ncbi.nlm.nih.gov/pubmed/22555152>

1624 Wong LY, Lui PY and Jin DY (2016). A molecular arms race between host innate antiviral response  
1625 and emerging human coronaviruses. *Viol Sin* **31**: 12-23  
1626 <https://www.ncbi.nlm.nih.gov/pubmed/26786772>

1627 Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL *et al.* (2020). Cryo-EM structure of the 2019-  
1628 nCoV spike in the prefusion conformation. *Science* **367**: 1260-1263  
1629 <https://www.ncbi.nlm.nih.gov/pubmed/32075877>

1630 Wu F, Zhao S, Yu B, Chen YM, Wang W *et al.* (2020). A new coronavirus associated with human  
1631 respiratory disease in China. *Nature* **579**: 265-269  
1632 <https://www.ncbi.nlm.nih.gov/pubmed/32015508>

1633 Xia S, Liu M, Wang C, Xu W, Lan Q *et al.* (2020). Inhibition of SARS-CoV-2 (previously 2019-nCoV)  
1634 infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that  
1635 harbors a high capacity to mediate membrane fusion. *Cell Res* **30**: 343-355  
1636 <https://www.ncbi.nlm.nih.gov/pubmed/32231345>

1637 Xiao F and Burns KD (2017). Measurement of Angiotensin Converting Enzyme 2 Activity in Biological  
1638 Fluid (ACE2). *Methods Mol Biol* **1527**: 101-115  
1639 <https://www.ncbi.nlm.nih.gov/pubmed/28116710>

1640 Xu J, Sriramula S, Xia H, Moreno-Walton L, Culicchia F *et al.* (2017). Clinical Relevance and Role of  
1641 Neuronal AT1 Receptors in ADAM17-Mediated ACE2 Shedding in Neurogenic Hypertension.  
1642 *Circ Res* **121**: 43-55 <https://www.ncbi.nlm.nih.gov/pubmed/28512108>

1643 Xu Z, Shi L, Wang Y, Zhang J, Huang L *et al.* (2020). Pathological findings of COVID-19 associated with  
1644 acute respiratory distress syndrome. *Lancet Respir Med* **8**: 420-422  
1645 <https://www.ncbi.nlm.nih.gov/pubmed/32085846>

1646 Yager EJ and Konan KV (2019). Sphingolipids as Potential Therapeutic Targets against Enveloped  
 1647 Human RNA Viruses. *Viruses* **11**: <https://www.ncbi.nlm.nih.gov/pubmed/31581580>  
 1648 Yan R, Zhang Y, Li Y, Xia L, Guo Y *et al.* (2020). Structural basis for the recognition of SARS-CoV-2 by  
 1649 full-length human ACE2. *Science* **367**: 1444-1448  
 1650 <https://www.ncbi.nlm.nih.gov/pubmed/32132184>  
 1651 Yang P, Kuc RE, Brame AL, Dyson A, Singer M *et al.* (2017). [Pyr<sup>1</sup>]Apelin-13<sub>1-12</sub> Is a Biologically Active  
 1652 ACE2 Metabolite of the Endogenous Cardiovascular Peptide [Pyr<sub>1</sub>]Apelin-13. *Front Neurosci*  
 1653 **11**: 92 <https://www.ncbi.nlm.nih.gov/pubmed/28293165>  
 1654 Yang S, Chen SJ, Hsu MF, Wu JD, Tseng CT *et al.* (2006). Synthesis, crystal structure, structure-activity  
 1655 relationships, and antiviral activity of a potent SARS coronavirus 3CL protease inhibitor. *J*  
 1656 *Med Chem* **49**: 4971-80 <https://www.ncbi.nlm.nih.gov/pubmed/16884309>  
 1657 Yang W, Ru Y, Ren J, Bai J, Wei J *et al.* (2019). G3BP1 inhibits RNA virus replication by positively  
 1658 regulating RIG-I-mediated cellular antiviral response. *Cell Death Dis* **10**: 946  
 1659 <https://www.ncbi.nlm.nih.gov/pubmed/31827077>  
 1660 Yang X, Chen X, Bian G, Tu J, Xing Y *et al.* (2014). Proteolytic processing, deubiquitinase and  
 1661 interferon antagonist activities of Middle East respiratory syndrome coronavirus papain-like  
 1662 protease. *J Gen Virol* **95**: 614-626 <https://www.ncbi.nlm.nih.gov/pubmed/24362959>  
 1663 Yeager CL, Ashmun RA, Williams RK, Cardellicchio CB, Shapiro LH *et al.* (1992). Human  
 1664 aminopeptidase N is a receptor for human coronavirus 229E. *Nature* **357**: 420-2  
 1665 <https://www.ncbi.nlm.nih.gov/pubmed/1350662>  
 1666 Yeo C, Kaushal S and Yeo D (2020). Enteric involvement of coronaviruses: is faecal-oral transmission  
 1667 of SARS-CoV-2 possible? *Lancet Gastroenterol Hepatol* **5**: 335-337  
 1668 <https://www.ncbi.nlm.nih.gov/pubmed/32087098>  
 1669 Yu P, Qi F, Xu Y, Li F, Liu P *et al.* (2020). Age-related rhesus macaque models of COVID-19. *Animal*  
 1670 *Model Exp Med* **3**: 93-97 <https://www.ncbi.nlm.nih.gov/pubmed/32318665>  
 1671 Zhang L, Lin D, Kusov Y, Nian Y, Ma Q *et al.* (2020).  $\alpha$ -Ketoamides as Broad-Spectrum Inhibitors of  
 1672 Coronavirus and Enterovirus Replication: Structure-Based Design, Synthesis, and Activity  
 1673 Assessment. *J Med Chem* <https://www.ncbi.nlm.nih.gov/pubmed/32045235>  
 1674 Zhang R, Wang K, Lv W, Yu W, Xie S *et al.* (2014). The ORF4a protein of human coronavirus 229E  
 1675 functions as a viroporin that regulates viral production. *Biochim Biophys Acta* **1838**: 1088-95  
 1676 <https://www.ncbi.nlm.nih.gov/pubmed/23906728>  
 1677 Zhao H, Zhu C, Qin C, Tao T, Li J *et al.* (2013). Fenofibrate down-regulates the expressions of  
 1678 androgen receptor (AR) and AR target genes and induces oxidative stress in the prostate  
 1679 cancer cell line LNCaP. *Biochem Biophys Res Commun* **432**: 320-5  
 1680 <https://www.ncbi.nlm.nih.gov/pubmed/23399562>  
 1681 Zhao J, Yang Y, Huang H, Li D, Gu D *et al.* (2020). Relationship between the ABO Blood Group and the  
 1682 COVID-19 Susceptibility. *medRxiv*  
 1683 <https://www.medrxiv.org/content/10.1101/2020.03.11.20031096v2>  
 1684 Zhao Q, Li S, Xue F, Zou Y, Chen C *et al.* (2008). Structure of the main protease from a global  
 1685 infectious human coronavirus, HCoV-HKU1. *J Virol* **82**: 8647-55  
 1686 <https://www.ncbi.nlm.nih.gov/pubmed/18562531>  
 1687 Zhong J, Basu R, Guo D, Chow FL, Byrns S *et al.* (2010). Angiotensin-converting enzyme 2 suppresses  
 1688 pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction. *Circulation* **122**: 717-  
 1689 28, 18 p following 728 <https://www.ncbi.nlm.nih.gov/pubmed/20679547>  
 1690 Zhou P, Fan H, Lan T, Yang XL, Shi WF *et al.* (2018). Fatal swine acute diarrhoea syndrome caused by  
 1691 an HKU2-related coronavirus of bat origin. *Nature* **556**: 255-258  
 1692 <https://www.ncbi.nlm.nih.gov/pubmed/29618817>

1693 Zhou Z, Sun Y, Yan X, Tang X, Li Q *et al.* (2020). Swine acute diarrhea syndrome coronavirus (SADS-  
 1694 CoV) antagonizes interferon-beta production via blocking IPS-1 and RIG-I. *Virus Res* **278**:  
 1695 197843 <https://www.ncbi.nlm.nih.gov/pubmed/31884203>

1696 Zhu N, Zhang D, Wang W, Li X, Yang B *et al.* (2020). A Novel Coronavirus from Patients with  
 1697 Pneumonia in China, 2019. *N Engl J Med* **382**: 727-733  
 1698 <https://www.ncbi.nlm.nih.gov/pubmed/31978945>

1699 Ziebuhr J, Schelle B, Karl N, Minskaia E, Bayer S *et al.* (2007). Human coronavirus 229E papain-like  
 1700 proteases have overlapping specificities but distinct functions in viral replication. *J Virol* **81**:  
 1701 3922-32 <https://www.ncbi.nlm.nih.gov/pubmed/17251282>

1702 Ziegler CGK, Allon SJ, Nyquist SK, Mbano IM, Miao VN *et al.* (2020). SARS-CoV-2 receptor ACE2 is an  
 1703 interferon-stimulated gene in human airway epithelial cells and is detected in specific cell  
 1704 subsets across tissues. *Cell*

1705 Zisman LS, Keller RS, Weaver B, Lin Q, Speth R *et al.* (2003). Increased angiotensin-(1-7)-forming  
 1706 activity in failing human heart ventricles: evidence for upregulation of the angiotensin-  
 1707 converting enzyme Homologue ACE2. *Circulation* **108**: 1707-12  
 1708 <https://www.ncbi.nlm.nih.gov/pubmed/14504186>

1709 Zumla A, Chan JF, Azhar EI, Hui DS and Yuen KY (2016). Coronaviruses - drug discovery and  
 1710 therapeutic options. *Nat Rev Drug Discov* **15**: 327-47  
 1711 <https://www.ncbi.nlm.nih.gov/pubmed/26868298>

1712